

RESEARCH

Open Access



The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019

João Vasco Santos^{1,2,3*}, Alicia Padron-Monedero⁴, Boris Bikbov⁵, Diana Alecsandra Grad^{6,7}, Dietrich Plass⁸, Enkeleint A. Mechili^{9,10}, Federica Gazzelloni¹¹, Florian Fischer¹², Gerhard Sulo¹³, Che Henry Ngwa¹⁴, Isabel Nogueira-Zambrano⁴, José L. Peñalvo¹⁵, Juanita A. Haagsma¹⁶, Katarzyna Kissimova-Skarbek¹⁷, Lorenzo Monasta¹⁸, Nermin Ghith¹⁹, Rodrigo Sarmiento-Suarez^{4,20}, Rok Hrzic²¹, Romana Haneef²², Rónán O’Caoimh^{23,24}, Sarah Cuschieri²⁵, Stefania Mondello²⁶, Zubair Kabir²⁷, GBD 2019 EU State of Health Collaborators, Alberto Freitas^{1,2} and Brecht Devleesschauwer^{28,29}

Abstract

Background The European Union (EU) faces many health-related challenges. Burden of diseases information and the resulting trends over time are essential for health planning. This paper reports estimates of disease burden in the EU and individual 27 EU countries in 2019, and compares them with those in 2010.

Methods We used the Global Burden of Disease 2019 study estimates and 95% uncertainty intervals for the whole EU and each country to evaluate age-standardised death, years of life lost (YLLs), years lived with disability (YLDs) and disability-adjusted life years (DALYs) rates for Level 2 causes, as well as life expectancy and healthy life expectancy (HALE).

Results In 2019, the age-standardised death and DALY rates in the EU were 465.8 deaths and 20,251.0 DALYs per 100,000 inhabitants, respectively. Between 2010 and 2019, there were significant decreases in age-standardised death and YLL rates across EU countries. However, YLD rates remained mainly unchanged. The largest decreases in age-standardised DALY rates were observed for “HIV/AIDS and sexually transmitted diseases” and “transport injuries” (each -19%). “Diabetes and kidney diseases” showed a significant increase for age-standardised DALY rates across the EU (3.5%). In addition, “mental disorders” showed an increasing age-standardised YLL rate (14.5%).

Conclusions There was a clear trend towards improvement in the overall health status of the EU but with differences between countries. EU health policymakers need to address the burden of diseases, paying specific attention to causes such as mental disorders. There are many opportunities for mutual learning among otherwise similar countries with different patterns of disease.

*Correspondence:

João Vasco Santos

jvasco.santos@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Key-points

- This article, systematically analysing GBD 2019 study estimates, presents an overview of the state of health in the European Union in 2019, compared to 2010.
- There was an improvement in the overall health status of the EU, despite substantial differences between Member States.
- Cardiovascular diseases and neoplasms are the major contributors to the overall burden of diseases in the EU in 2019.
- The age-standardised rate of years lived with disability due to mental disorders has been increasing and is expected to increase even more because of the COVID-19 pandemic.
- This report provides a framework upon which to base further region- and country-specific health policies and interventions, to support health planning and priority setting.

Keywords European Union, Health status, Population health, Global Burden of Diseases, European Burden of Disease Network

Introduction

The European Union (EU) faces many challenges that impact current and future population health, including complex issues such as population ageing, digital and green transitions, socio-economic challenges and the organisation of health systems. In addition, there are still significant differences in health status between EU countries which are associated with factors such as structural and budgetary differences, variations in the effectiveness of public health policies and health related risk factors [1–6]. In fact, health systems differ across the EU and, for instance, while the 2008 global financial crisis reduced annual health budgets, this did not happen uniformly. In addition, as population ageing advances, multimorbidity and frailty are becoming more common and need to be addressed to improve the well-being of EU countries [7–9].

According to Eurostat, life expectancy at birth in the EU was 81.0 years in 2019, with women living, on average, 5.5 years longer than men [4, 10]. Beyond life expectancy, population health can be summarised through combined health metrics such as health-adjusted life expectancy (HALE) and disability-adjusted life years (DALYs). DALYs consist of two components: (i) years of life lost (YLLs), which captures health loss due to premature mortality, and (ii) years lived with disability (YLDs), which quantifies health loss due to morbidity. A previous study showed a decline in YLD and DALY rates, an increase in life expectancy of 5.9 years and an increase in HALE of 4.6 years, on average, from 1990 to 2017 among EU-28 countries [11]. However, another study concluded that, despite the improvement in the health status of the EU, several central and eastern European countries had not experienced such pronounced gains in overall health in comparison to the EU-15 [12].

Accurate and timely data on mortality and morbidity, caused by diseases and injuries and their trends over time are essential to assess the impact of health strategies and assist policy makers in improving health planning and priority setting. This information can also be used to understand between-region variations, providing opportunities for mutual learning among EU countries. The Global Burden of Disease (GBD) study generates estimates of population health using a wide range of metrics, capturing the impact of diseases, injuries and risk factors on health. Furthermore, it allows for comprehensive comparisons over time and across countries. Burden of disease estimates are increasingly used in the EU and globally, as they provide a comprehensive and comparable picture of the overall population health status. An earlier analysis of the results from the GBD 2017 study for the EU countries examined changes since 2007 for the burden of diseases and injuries in the EU-28 in 2017 [13]. Between the release of the GBD 2017 and the GBD 2019 datasets, several improvements were made, including key demographic modelling steps, preferred/reference case definitions or measurement methods and the development of a Bayesian meta-regression tool, as well as the inclusion of more data sources and 12 new causes [14, 15].

In this paper, we analyse the GBD 2019 study estimates (focusing on deaths, YLDs, YLLs, DALYs, life expectancy and HALE) and compare the years 2019 and 2010 to describe the current health status of the EU. The aim of this study is to provide a picture of the state of health in the EU-27 countries in 2019, to examine how these have changed since 2010 and to highlight meaningful opportunities that exist to improve health across the continent.

Methods

Data source and overview of the GBD 2019 study

We obtained estimates from the 2019 GBD study for the EU-27 region and for the 27 EU countries individually. Considering the period of analysis, the 27 EU member states countries included were: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

A detailed description of methods and results used in GBD 2019 has been published elsewhere [14–17]. In brief, the GBD 2019 study is a collaborative effort of more than 5,000 researchers, aiming to measure population health at global, regional and national levels by quantifying the burden of 369 diseases and injuries (i.e. 286 causes of death and 364 non-fatal causes) and 87 risk factors between 1990 and 2019 for 204 countries and territories. Several improvements were made in the GBD 2019 study, including key demographic modelling steps, reference case definitions or measurement methods and the Bayesian meta-regression tool. In addition, more data sources and 12 new causes were added to the GBD modelling framework, including pulmonary arterial hypertension, nine new sites of cancer, and two new sites of osteoarthritis (hand and other joints). The GBD produces estimates of incidence, prevalence, mortality, YLDs, YLLs, DALYs, life expectancy and HALE for the entire time span between 1990 and 2019. Cause-specific death rates and cause fractions are calculated using the Cause of Death Ensemble model (CODEm) and spatiotemporal Gaussian process regression. They are adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates [15, 18].

DALYs consist of two main components: YLLs and YLDs. YLLs are calculated by multiplying the number of deaths of each age the remaining life expectancy (RLE) at age of death derived from the GBD standard life Table [19]. YLDs are estimated by multiplying the prevalence counts by the disability weight for each specific health outcome associated with a given disease or injury, with further adjustment for co-morbidity and severity. A Bayesian meta-regression modelling tool, DisMod-MR (Disease Modelling-Meta Regression) 2.1, ensures consistency between all epidemiologic metrics for most causes [16]. HALE accounts for years of life spent in good health and serves as a summary for both mortality and morbidity [13]. It thus corresponds to specific LE by age and geography, adjusted for the years spent living with disability and disability weights. All estimates are reported with their 95% uncertainty intervals (UI). UIs are propagated throughout the estimating process where

1000 draws are generated for each point estimate, and the 95% UIs are obtained by selecting the 2.5th and 97.5th percentiles of the draws. This approach ensures robustness in identifying meaningful differences and trends in health outcomes over time.

Analytic strategies

The statistical significance of the difference between two estimates was defined as the absence of overlap between the 95% UI of those estimates. We analysed the overall (all ages and both sexes) and age group-specific rates for men and women. To analyse trends between 2010 and 2019, we relied on age-standardised rates and their relative changes since 2010. Difference between 2010 and 2019 was expressed in percentage change since 2010 (i.e. $\%change_{2010-2019} = \frac{estimate_{2019} - estimate_{2010}}{estimate_{2010}} \times 100$). In the GBD 2019 study, the same methodology is applied across years, including for 2010 and 2019. Age-standardisation is based on the GBD 2019 world standard population, which adjusts for differences in age distributions across populations, ensuring comparability between groups with different age structures. These rates were calculated using methodologies outlined in the GBD study, which provides upper and lower bounds of the estimates, allowing for a comprehensive analysis of trends over time.

The GBD arranges diseases and injuries (causes) into hierarchically nested categories in four levels of aggregation. At every level of aggregation, causes are mutually exclusive and collectively exhaustive. We extended this analysis focusing on each of the 22 Level 2 causes, and including seven Level 2 causes from Level 1 in the “communicable, maternal, neonatal and nutritional diseases” group (enteric infections, respiratory infections and tuberculosis, HIV/AIDs and sexually transmitted infections, maternal and neonatal disorders, neglected tropical diseases and malaria, nutritional deficiencies, other infectious diseases), 12 in the “non-communicable diseases” (NCDs) group (cardiovascular diseases, chronic respiratory diseases, diabetes and kidney diseases, digestive diseases, mental disorders, musculoskeletal disorders, neoplasm, neurological disorders, sense organ diseases, skin and subcutaneous diseases, substance use disorders, other NCDs), and three in the “injuries” group (self-harm and interpersonal, unintentional injuries and transport injuries). We considered Level 2 causes to focus the analysis on broad disease categories due to their policy implications. These causes represent broad disease categories where policy implications can result in benefits for all conditions summarized in these broader categories. We thus provide insights into the major drivers of health outcomes within the population.

All results are based on the estimates extracted from the Global Burden of Disease Results database and GBD

Compare [20, 21]. All analyses were carried out with the open-source R Statistical Software (version 3.4, Foundation for Statistical Computing, Vienna, Austria) [22]. The GBD study adheres to the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) standards developed by WHO and others [23].

Results

Overall disease burden in the European Union

In 2019, the EU-27 had a total of 5,354,279 (95% UI: 5,206,626; 5,502,691) all-cause deaths, yielding a crude death rate of 1040.3 (95% UI: 1011.6; 1069.1) per 100 000 inhabitants. The age-standardised death rate for all causes was 465.8 (95% UI: 451.2; 480.9) per 100,000 inhabitants in the EU, with high variability across countries, ranging from 894.8 per 100,000 in Bulgaria to 385.9 per 100,000 in Spain. The total number of all-cause DALYs was 157,884,271 (95% UI: 139,041,970; 178,511,173), with a crude rate of 30,675 (95% UI: 27,014; 34,683) per 100,000 inhabitants. The all-cause age-standardised DALY rate per 100 000 inhabitants in 2019 was 20 251.0 (95% UI: 17 408.1; 23 513.9).

Eight countries (Bulgaria, Romania, Latvia, Hungary, Lithuania, Slovakia, Croatia, and Poland) reported significantly higher (i.e., the lower limit of the individual country 95% UI was higher than the upper limit of the EU 95% UI) all-cause age-standardised death rates than the EU. In contrast, nine countries (Spain, Italy, France, Luxembourg, Sweden, Malta, Austria, Finland, and Ireland) had significantly lower rates than the EU (Fig. 1A; Table 1). The all-cause age-standardised death rate in the EU declined on average by 8.8% (95% UI: -11.7; -5.9), ranging from -4.8% (95% UI: -7.2; -2.3) in Greece to -18.5% (95% UI: -30.7%; -4.5%) in Lithuania.

In 2019, compared to the EU, all-cause age-standardised DALY rates were significantly higher only in Bulgaria (Fig. 1B; Table 1). All-cause age-standardised DALY rates have declined significantly since 2010 (i.e., the upper limit of the 95% UI below zero) in most countries, except for Bulgaria, Croatia, Czechia, Estonia, Hungary, Romania, Slovakia, and Slovenia. Whilst most countries showed a decreasing trend in all-cause age-standardised YLL rates, no significant changes were found in all-cause age-standardised YLD rates between 2010 and 2019. Only Belgium, Lithuania, Portugal, and Slovenia experienced significant declines, while the Netherlands experienced significant increases in YLD rates (Table 1).

In 2019, life expectancy in the EU at birth was 81.0 years, ranging from 73.3 years in Bulgaria to 83.1 years in Italy and Spain. All countries experienced improvements in life expectancy between 2010 and 2019, with Lithuania having the highest increase (4.5%) and the EU-27 showing a 1.4% increase (from

79.8 years to 81.0 years). HALE at birth for the EU in 2019 was 69.8 years, ranging from 64.6 years in Bulgaria to 71.6 years in Spain, with HALE at birth improving by 1.2% between 2010 (i.e. 69.0 years) and 2019 across the EU-27. However, the gap between life expectancy and HALE widened from 10.8 years (13.6% of LE) in 2010 to 11.2 in 2019 (13.8% of LE), which suggests that YLDs represent a growing share of DALY rates.

Overall disease burden by age and sex

DALY rates increased similarly with age in both males and females. However, across the EU in 2019, for most age groups, DALY rates were higher among males than females (Fig. 2). For males, DALY rates were mostly driven by YLLs in those aged above 44 years of age and by YLDs among younger (< 44 years old) age groups. For females, this cut-off occurred at a more advanced age, with DALY rates mostly driven by YLLs in groups aged above 64 years. YLLs dominated over YLDs in both sexes particularly in age extremes, i.e. younger and older age groups (Fig. 2).

Main causes of ill health

In 2019, the age-standardised death rates for cardiovascular diseases were significantly higher than the EU rate (159.0; 95% UI 142.2; 169.2) in most Central and Eastern European countries, with the highest values in Bulgaria, Romania, and Latvia, and significantly lower than the EU rate in some Western European countries (Fig. 1A). A similar geographic pattern was observed for age-standardised DALY rates for cardiovascular diseases, the second leading cause of age-standardised DALY in the EU (Fig. 1B).

Compared to the EU, the age-standardized death (143.6; 95% UI 133.8; 150.1) and DALY (3,342; 95% UI 3,175; 3,505) rates for neoplasms in 2019 were significantly lower in Spain, Sweden, Malta, Austria, and Finland (Fig. 1A and B). Hungary and Netherlands showed a significantly higher age-standardised death rate, with Hungary and Poland having a significantly higher age-standardized DALY rate (Fig. 1A and B). In fact, the age-standardised death rate in Hungary was almost two times higher than in France. Neoplasms were the leading cause of age-standardized DALY and the second highest cause of age-standardised mortality across the EU in 2019.

Digestive diseases are another example of high variability in death rates in EU countries. The highest (in Romania) to the lowest (in Malta) age-standardised death rates ratio is over 3.2. Additionally, countries of Central and Eastern Europe (Romania, Lithuania, Bulgaria, Hungary, Slovakia, Latvia, Poland) had significantly higher DALY rates than the EU rate.

A	Level 2 causes																					
	All causes	Cardiovascular diseases	Neoplasms	Neurological disorders	Digestive diseases	Chronic respiratory diseases	Diabetes and kidney diseases	Respiratory infections and tuberculosis	Unintentional injuries	Self-harm and interpersonal violence	Other non-communicable diseases	Transport injuries	Substance use disorders	Maternal and neonatal disorders	Musculoskeletal disorders	Enteric infections	Skin and subcutaneous diseases	Other infectious diseases	HIV/AIDS and sexually transmitted infections	Nutritional deficiencies	Mental disorders	Neglected tropical diseases and malaria
EU-27	465.8	159.0	143.6	31.0	23.8	22.0	19.0	15.0	13.1	10.2	9.1	6.2	4.8	3.3	1.4	1.1	1.0	1.0	0.6	0.6	0.02	0.02
Spain	385.9	106.8	127.4	29.6	21.0	29.0	19.2	11.4	8.9	6.4	10.3	5.5	1.8	2.7	1.2	1.0	1.3	0.9	1.1	0.4	0.01	0.03
Italy	386.8	126.1	129.1	31.7	17.7	16.8	20.9	6.8	9.4	5.7	7.2	6.8	1.2	2.8	1.2	0.6	0.7	0.9	0.8	0.4	0.01	0.02
France	387.5	91.4	140.5	31.8	19.6	12.8	14.2	12.3	19.2	13.3	9.1	6.4	5.6	3.4	1.9	0.9	1.3	1.1	0.6	2.2	0.03	0.01
Luxembourg	389.2	116.0	127.5	28.9	20.2	19.9	16.3	11.8	13.7	9.7	6.2	5.9	5.2	2.0	0.9	1.5	0.7	1.7	0.4	0.6	0.03	0.06
Sweden	397.9	138.6	120.9	29.0	14.2	17.8	16.0	10.9	11.8	11.9	7.1	3.4	6.7	2.2	1.5	2.7	1.4	1.1	0.2	0.5	0.01	0.01
Malta	400.4	146.7	108.9	29.4	13.4	15.4	22.7	18.9	10.0	5.5	10.2	4.7	2.3	5.5	1.0	0.3	4.0	0.9	0.3	0.1	0.01	0.18
Austria	420.8	150.6	122.3	28.7	18.2	16.9	26.2	5.9	12.5	12.0	11.2	5.2	5.0	2.7	1.1	0.6	0.4	0.8	0.3	0.1	0.05	0.02
Finland	428.4	173.8	115.0	31.0	22.9	14.6	8.7	5.6	15.3	14.4	5.9	4.9	11.6	1.6	1.4	0.3	0.4	0.8	0.1	0.1	0.01	0.01
Ireland	430.5	132.8	137.9	31.0	15.6	32.4	15.3	22.2	8.2	8.7	10.3	3.4	5.4	2.6	2.1	0.7	1.0	0.8	0.2	0.1	0.01	0.00
Portugal	439.9	127.9	131.1	28.2	21.9	23.7	28.3	28.5	10.0	9.3	11.4	7.7	1.5	2.6	1.1	0.9	0.8	0.9	3.7	0.6	0.00	0.06
Netherlands	443.1	113.0	163.0	33.0	17.9	28.6	18.9	16.7	13.1	9.9	11.8	3.8	2.6	3.6	1.9	1.1	2.0	1.3	0.2	0.5	0.04	0.01
Slovenia	447.4	151.1	144.4	31.2	26.0	12.7	12.3	13.3	17.9	14.5	5.8	6.7	7.2	1.8	1.2	0.1	0.3	0.6	0.1	0.0	0.00	0.01
Belgium	449.5	118.6	143.9	30.9	22.8	27.6	16.3	21.6	17.1	16.3	10.4	7.1	4.6	2.9	1.4	3.0	1.8	1.5	0.4	1.2	0.02	0.01
Denmark	462.4	118.8	157.6	29.1	23.3	36.0	20.6	18.7	10.8	9.2	10.3	4.5	11.8	3.6	2.4	2.9	0.9	1.1	0.4	0.6	0.01	0.01
Germany	462.5	159.4	140.5	30.6	25.0	24.8	11.3	11.3	10.2	9.3	4.7	6.3	3.0	0.9	1.8	1.0	0.9	0.4	0.3	0.03	0.01	0.01
Greece	472.9	186.8	143.3	28.2	15.2	20.4	20.1	19.4	9.3	4.5	7.1	11.1	2.1	3.4	0.5	0.2	0.2	0.7	0.2	0.0	0.02	0.07
Cyprus	519.4	190.3	121.8	31.0	21.8	32.5	48.1	11.8	15.3	5.6	14.1	14.4	1.6	3.4	2.0	1.4	2.7	0.7	0.3	0.5	0.00	0.02
Czechia	541.0	232.2	145.9	30.2	24.9	18.4	21.5	16.3	16.1	11.5	6.4	7.1	3.9	2.5	0.6	1.4	0.6	0.7	0.2	0.6	0.00	0.01
Poland	583.8	235.6	175.2	32.1	28.0	15.4	17.8	17.8	16.0	15.0	6.8	9.5	8.6	3.1	0.9	0.4	0.3	0.7	0.3	0.2	0.01	0.01
Estonia	584.3	270.6	144.8	30.8	25.0	10.3	16.8	10.5	18.0	15.9	6.3	6.0	22.1	1.7	1.1	0.1	0.7	0.9	2.6	0.1	0.00	0.00
Croatia	591.3	265.8	159.8	31.7	26.4	19.5	21.6	7.1	18.8	12.0	8.7	8.4	5.1	3.7	1.1	0.4	0.2	0.6	0.2	0.0	0.00	0.01
Slovakia	623.9	298.9	152.8	29.7	34.6	12.6	17.4	22.1	18.6	11.6	7.7	8.0	3.2	4.3	0.5	0.3	0.4	0.9	0.2	0.1	0.00	0.01
Lithuania	666.1	328.8	140.0	29.5	37.5	12.2	8.7	14.0	28.2	28.4	8.1	8.6	14.3	2.3	1.0	0.3	0.9	1.2	1.9	0.1	0.00	0.01
Hungary	667.5	301.6	181.9	29.9	36.0	29.7	21.3	7.0	16.9	14.8	8.8	7.3	4.1	3.5	1.3	1.4	0.6	0.8	0.4	0.2	0.00	0.01
Latvia	685.3	356.8	143.4	28.3	26.9	9.9	14.5	12.1	26.3	21.7	9.8	9.8	13.1	3.1	1.0	0.1	1.3	1.4	5.6	0.2	0.00	0.05
Romania	716.5	379.6	148.3	29.1	43.2	20.8	14.3	24.9	17.0	10.2	6.5	11.5	2.5	5.4	0.3	0.4	0.3	1.1	0.8	0.3	0.00	0.03
Bulgaria	894.8	541.1	161.0	31.9	35.3	20.5	30.2	17.7	15.0	13.0	8.2	9.8	2.0	5.5	0.4	0.4	0.3	1.6	0.6	0.1	0.00	0.10

B	Level 2 causes																						
	All causes	Neoplasms	Cardiovascular diseases	Musculoskeletal disorders	Mental disorders	Other non-communicable diseases	Neurological disorders	Unintentional injuries	Diabetes and kidney diseases	Digestive diseases	Chronic respiratory diseases	Skin and subcutaneous diseases	Substance use disorders	Self-harm and interpersonal violence	Sense organ diseases	Maternal and neonatal disorders	Transport injuries	Respiratory infections and tuberculosis	Nutritional deficiencies	Enteric infections	Other infectious diseases	HIV/AIDS and sexually transmitted infections	Neglected tropical diseases and malaria
EU-27	20251	3342	2759	2020	1874	1550	1408	1118	797	765	754	684	603	491	484	452	427	369	144	100	56	44	12
Spain	18033	2977	1834	1831	2192	1472	1350	910	789	551	752	698	469	309	538	380	349	281	125	84	54	66	20
Italy	18186	2976	2032	2184	1954	1532	1472	784	814	644	539	733	344	284	530	413	422	225	145	59	47	51	4
France	18782	3311	1628	2055	2045	1602	1426	1279	463	565	554	843	567	609	402	419	418	278	149	72	56	40	2
Luxembourg	18634	2933	1981	2141	1850	1496	1366	1091	804	610	787	728	664	467	380	347	389	275	117	108	71	28	4
Sweden	18069	2672	2329	2036	2017	1386	1321	1010	615	466	786	692	591	340	311	241	265	123	110	46	18	3	3
Malta	18983	2604	2511	2224	1903	1740	1329	1075	919	429	674	748	466	311	405	670	316	394	111	58	55	26	13
Austria	19104	2820	2408	1971	1905	1932	1326	1083	790	674	651	711	659	552	392	412	332	208	103	77	49	33	17
Finland	19569	2606	2864	2037	1887	1484	1396	1396	685	788	618	748	925	734	388	267	323	198	100	68	43	10	3
Ireland	19401	3049	2193	2273	2202	1666	1404	936	622	465	969	728	824	474	397	360	236	373	95	69	46	17	2
Portugal	19674	3135	2150	2256	2317	1428	1291	780	980	624	861	733	477	422	413	374	422	527	136	74	54	199	21
Netherlands	18888	3614	1883	2001	2069	1663	1414	874	637	438	977	721	428	480	371	477	251	321	109	74	60	24	2
Slovenia	19135	3341	2546	1521	1462	1337	1249	1694	697	864	505	451	621	665	568	366	635	277	127	143	42	14	8
Belgium	20170	3256	2021	2042	1875	1788	1579	1267	694	641	879	730	601	769	409	415	440	404	126	131	69	35	2
Denmark	19929	3494	1968	2485	1794	1709	1282	926	678	686	1030	776	890	423	374	459	289	347	109	127	53	28	3
Germany	20075	3221	2601	2211	1898	1692	1539	970	894	742	749	717	618	477	393	442	315	287	122	109	45	29	3
Greece	20201	3300	3198	2031	2260	1591	1330	947	790	470	724	677	432	242	419	476	672	408	83	69	45	18	19
Cyprus	19743	2648	2939	2225	1915	1556	1330	1064	1165	483	864	719	358	311	397	457	773	264	112	99	38	22	3
Czechia	21153	3405	3909	1548	1385	1271	1269	1561	1251	896	628	454	515	577	595	434	656	395	142	189	49	17	8
Poland	22749	4192	4183	1629	1259	1216	1337	1570	951	1033	651	460	765	743	637	437	768	478	196	121	55	27	42
Estonia	23061	3522	4651	1510	1573	1345	1337	1580	752	987	354	553	1646	773	642	317	517	424	130	186	62	167	31
Croatia	21886	3770	4267	1600	1451	1513	1289	1449	981	898	632	444	523	558	606	558	752	228	122	150	45	17	33
Slovakia	23352	3762	5134	1541	1373	1564	1281	1792	848	1242	476	451	477	572	606	544	653	559	162	182	76	22	36
Lithuania	25648	3573	5824	1496	1716	1619	1242	2020															

Table 1 All-cause age-standardised death, YLL, YLD and DALY rates (per 100 000 inhabitants), life expectancy and healthy life expectancy for the European Union and for each EU country in 2019 and their percentage change between 2010 and 2019

	AS Death rate		AS YLL rate		AS YLD rate		AS DALY rate		Life expectancy		Health-adjusted life expectancy	
	2019	2010-2019 (%)	2019	2010-2019 (%)	2019	2010-2019 (%)	2019	2010-2019 (%)	2019	2010-2019 (%)	2019	2010-2019 (%)
European Union	465.8 (451.2; 480.9)	-8.8 (-11.7; -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (+0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7)	81.0 (80.6; 81.3)	1.4 (1.0; 1.9)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Austria	420.8 (413.4; 428.8)	-11.2 (-12.9; -9.4)	8360 (8154; 8584)	-14.9 (-17.2; -12.5)	10,744 (7927; 13,927)	-0.4 (-2; 1.2)	19,104 (16,292; 22,253)	-7.3 (-9.2; -5.6)	82.2 (82; 82.3)	1.7 (1.4; 2)	70.6 (67.2; 73.6)	1.6 (1.2; 1.9)
Belgium	449.5 (439.6; 460.2)	-9.4 (-11.6; -7.2)	9129 (8837; 9453)	-12.5 (-15.4; -9.4)	11,041 (8083; 14,321)	-2.1 (-3.7; -0.3)	20,170 (17,230; 23,435)	-7.1 (-9; -5.1)	81.4 (81.2; 81.6)	1.5 (1.2; 1.8)	69.7 (66.3; 72.8)	1.5 (1.1; 2)
Bulgaria	894.8 (744.3; 1070.7)	-7.1 (-23.7; 11)	19,339 (15,632; 23,799)	-9.4 (-27.9; 11.4)	10,036 (7413; 12,976)	0.3 (-1.5; 2.3)	29,375 (24,710; 34,547)	-6.3 (-18.7; 8)	73.3 (70.9; 75.7)	1.4 (-2; 4.9)	64.6 (61.4; 67.6)	1.3 (-1.9; 4.3)
Croatia	591.3 (486.8; 714.9)	-14.2 (-29.4; 3.6)	11,612 (9294; 14,433)	-16.7 (-33.4; 3.5)	10,274 (7607; 13,342)	0.2 (-2.1; 2.5)	21,886 (18,219; 26,054)	-9.5 (-19.5; 2)	78.7 (76.5; 80.8)	2.4 (-0.4; 5.2)	68.2 (64.8; 71.5)	2 (-0.5; 4.2)
Cyprus	519.4 (480.7; 563.4)	-14.4 (-21; -7.1)	9235 (8394; 10,194)	-12.4 (-20.6; -3)	10,508 (7709; 13,612)	0.4 (-1.1; 1.7)	19,743 (16,838; 22,880)	-6 (-10.7; -1.4)	80.8 (80; 81.6)	1.6 (0.6; 2.6)	69.9 (66.7; 72.9)	1.4 (0.5; 2.3)
Czechia	541 (457.8; 638.7)	-12.1 (-25.5; 3.6)	10,745 (8899; 12,953)	-15.2 (-29.7; 2.2)	10,409 (7680; 13,558)	0.2 (-1.8; 2.3)	21,153 (17,813; 24,971)	-8.2 (-16.7; 1.5)	79.5 (77.6; 81.3)	2.1 (-0.4; 4.4)	68.6 (65.1; 71.7)	1.7 (-0.4; 3.6)
Denmark	462.4 (449.3; 476.6)	-13.2 (-15.9; -10.5)	9162 (8798; 9566)	-14.9 (-18.4; -11.1)	10,768 (7956; 13,905)	-0.1 (-1.6; 1.6)	19,929 (17,111; 23,155)	-7.5 (-10; -5.2)	81.1 (80.8; 81.4)	2 (1.6; 2.4)	69.9 (66.7; 72.8)	1.7 (1.3; 2.2)
Estonia	584.3 (477.6; 707.2)	-12.8 (-28.8; 6)	13,026 (10,488; 16,078)	-15.4 (-32; 4.1)	10,035 (7400; 13,058)	-0.3 (-2.5; 1.8)	23,061 (19,316; 27,134)	-9.5 (-19.9; 2.3)	78 (75.6; 80.5)	2.4 (-0.9; 5.6)	68.1 (64.7; 71.4)	2.2 (-0.7; 5)
Finland	428.4 (414.9; 443.1)	-11.6 (-14.5; -8.5)	8765 (8419; 9144)	-15.4 (-18.9; -11.7)	10,805 (7991; 14,005)	-1.1 (-2.7; 0.6)	19,569 (16,724; 22,872)	-8.1 (-10.5; -5.9)	81.9 (81.5; 82.2)	1.8 (1.3; 2.3)	70.3 (67; 73.3)	1.8 (1.3; 2.3)
France	387.5 (380.3; 395.2)	-10.7 (-12.5; -8.9)	8282 (8061; 8526)	-13 (-15.5; -10.4)	10,499 (7719; 13,653)	0 (-1.8; 2)	18,782 (16,017; 21,919)	-6.2 (-8.2; -4.2)	82.9 (82.7; 83.1)	1.6 (1.3; 1.8)	71.5 (68.1; 74.5)	1.3 (0.9; 1.7)
Germany	462.5 (455.3; 471.1)	-5.2 (-6.7; -3.4)	9126 (8946; 9330)	-8.2 (-10.1; -6.2)	10,949 (8072; 14,255)	0.7 (-1.8; 3.2)	20,075 (17,158; 23,315)	-3.6 (-5.3; -1.7)	81.2 (81; 81.4)	0.9 (0.6; 1.1)	69.7 (66.4; 72.7)	0.6 (0.1; 1)

Table 1 (continued)

	AS Death rate		AS YLL rate		AS DALY rate		Life expectancy		Health-adjusted life expectancy		
	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	
European Union	465.8 (451.2; 480.9)	-8.8 (-11.7; -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (-0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7)	81.0 (80.6; 81.3)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Greece	472.9 (461.8; 485.2)	-4.8 (-7.2; -2.3)	9543 (9206; 9929)	-6.1 (-9.6; -2.3)	10,658 (7853; 13,819)	-0.5 (-2.2; 1.3)	20,201 (17,423; 23,370)	-3.2 (-5.4; -1)	80.9 (80.7; 81.2)	69.9 (66.7; 72.7)	0.7 (0.2; 1.1)
Hungary	667.5 (566.5; 785.6)	-13.1 (-26.1; 2.2)	14,296 (11,873; 17,181)	-15.9 (-30.1; 1)	10,204 (7532; 13,215)	0.4 (-1.6; 2.4)	24,500 (20,800; 28,629)	-9.8 (-18.7; 0.8)	76.6 (74.6; 78.6)	66.8 (63.6; 69.9)	2.1 (-0.2; 4.2)
Ireland	430.5 (416.4; 446)	-9.7 (-12.9; -6.4)	8320 (7935; 8752)	-14.5 (-18.6; -10.1)	11,081 (8177; 14,373)	0.2 (-1.5; 2)	19,401 (16,512; 22,745)	-6.7 (-9.4; -4.2)	82 (81.7; 82.4)	70.4 (67; 73.3)	1.3 (0.7; 1.8)
Italy	386.8 (383.4; 390.1)	-9.2 (-10.1; -8.4)	7439 (7344; 7527)	-11.5 (-12.7; -10.4)	10,746 (7879; 14,084)	0.1 (-0.6; 0.8)	18,186 (15,294; 21,486)	-5 (-6.1; -4)	83.1 (83; 83.2)	71.2 (67.8; 74.3)	1 (0.9; 1.2)
Latvia	685.3 (596.3; 797.8)	-15.7 (-26.6; -1.9)	15,938 (13,622; 18,804)	-19.9 (-31.5; -5.8)	10,078 (7427; 13,078)	-1 (-2.8; 0.9)	26,016 (22,399; 30,171)	-13.5 (-21.6; -3.9)	75.9 (73.8; 77.7)	66.3 (63.2; 69.2)	3.3 (0.9; 5.6)
Lithuania	666.1 (565.5; 780)	-18.5 (-30.7; -4.5)	15,538 (13,039; 18,462)	-22.8 (-35; -8.1)	10,111 (7490; 13,073)	-2.1 (-4; -0.1)	25,648 (21,935; 29,654)	-15.8 (-24; -5.9)	76.2 (74.1; 78.3)	66.6 (63.3; 69.6)	4 (1.4; 6.4)
Luxembourg	389.2 (353.4; 432.3)	-16.8 (-24.7; -7.4)	7794 (6939; 8847)	-16 (-25.7; -4.5)	10,840 (8014; 14,065)	-0.1 (-2; 1.8)	18,634 (15,642; 22,023)	-7.4 (-12.3; -1.9)	82.9 (81.8; 83.9)	71 (67.5; 74.1)	1.9 (0.6; 3.1)
Malta	400.4 (365.8; 438.7)	-13.1 (-20.3; -5.3)	8350 (7400; 9502)	-12.7 (-22.6; -1.1)	10,633 (7845; 13,777)	-0.2 (-1.7; 1.3)	18,983 (16,094; 22,345)	-6.1 (-11.2; -0.6)	82.6 (81.6; 83.5)	71.1 (67.7; 74.1)	1.5 (0.5; 2.6)
Netherlands	443.1 (432.3; 454.7)	-6.6 (-8.9; -4.1)	8503 (8200; 8844)	-9 (-12.3; -5.4)	10,385 (7710; 13,439)	2.3 (0.4; 4.5)	18,888 (16,190; 22,000)	-3.1 (-5.4; -0.8)	81.7 (81.5; 82)	70.6 (67.5; 73.4)	0.4 (-0.1; 0.9)
Poland	583.8 (504.2; 672.3)	-11.2 (-23.5; 2.1)	12,787 (10,894; 14,824)	-14.5 (-27.1; -0.5)	9963 (7364; 12,907)	0.1 (-0.7; 0.8)	22,749 (19,421; 26,563)	-8.7 (-16.6; -0.2)	78.1 (76.3; 79.9)	68.1 (64.8; 71.2)	1.9 (-0.1; 3.8)
Portugal	439.9 (429.4; 451.3)	-12 (-14.3; -9.6)	8774 (8463; 9122)	-15.3 (-18.4; -11.8)	10,900 (8009; 14,120)	-2.2 (-3.8; -0.8)	19,674 (16,845; 22,930)	-8.5 (-10.7; -6.5)	81.7 (81.5; 82)	70.2 (66.8; 73.2)	2 (1.6; 2.4)

Table 1 (continued)

	AS Death rate		ASYLL rate		ASYLD rate		AS DALY rate		Life expectancy		Health-adjusted life expectancy	
	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)	2019	2010–2019 (%)
European Union	465.8 (451.2; 480.9)	-8.8 (-11.7; -5.9)	9564 (9158; 9997)	-12 (-15.7; -8.1)	10,687 (7908; 13,858)	0.6 (-0.1; 1.2)	20,251 (17,408; 23,514)	-5.8 (-8; -3.7)	81.0 (80.6; 81.3)	1.4 (1.0; 1.9)	69.8 (66.6; 72.7)	1.2 (0.7; 1.6)
Romania	716.5 (611.7; 835.4)	-12.2 (-25.1; 2.2)	16,199 (13,757; 19,117)	-14.6 (-27.5; 0.5)	9844 (7318; 12,819)	0.1 (-2; 2.2)	26,044 (22,457; 29,967)	-9.6 (-18.4; 0.7)	75.5 (73.5; 77.5)	2.4 (-0.3; 5)	66.4 (63.3; 69.2)	2.1 (-0.3; 4.4)
Slovakia	623.9 (511.6; 756.9)	-12.6 (-28.6; 6)	13,208 (10,559; 16,428)	-15 (-32.1; 5.3)	10,144 (7480; 13,113)	0 (-2.1; 2.1)	23,352 (19,472; 27,684)	-9.1 (-19.4; 3.3)	77.6 (75.2; 79.9)	2.3 (-0.8; 5.4)	67.6 (64.1; 70.8)	2 (-0.7; 4.5)
Slovenia	447.4 (362.1; 560.3)	-14.2 (-30.3; 6.9)	9023 (7218; 11,474)	-16.2 (-32.7; 6.4)	10,112 (7485; 13,119)	-2.5 (-4.4; -0.8)	19,135 (15,775; 23,040)	-9.5 (-18.5; 2.1)	81.4 (78.9; 83.7)	2.1 (-1; 5)	70.4 (66.7; 73.9)	2.2 (-0.6; 4.5)
Spain	385.9 (378.7; 393.6)	-8.9 (-10.6; -7)	7570 (7372; 7792)	-11.4 (-13.8; -8.8)	10,463 (7734; 13,596)	1.3 (-0.5; 3.1)	18,033 (15,282; 21,170)	-4.5 (-6.3; -2.6)	83.1 (82.9; 83.3)	1.2 (1; 1.5)	71.6 (68.3; 74.5)	0.9 (0.5; 1.3)
Sweden	397.9 (393.1; 403)	-8.5 (-9.9; -7.2)	7595 (7477; 7723)	-10.2 (-11.8; -8.5)	10,474 (7727; 13,605)	0.9 (-0.5; 2.2)	18,069 (15,379; 21,133)	-4.1 (-5.5; -2.8)	82.8 (82.7; 83)	1.2 (1; 1.4)	71.4 (68.1; 74.3)	0.9 (0.6; 1.2)




Fig. 2 Disability adjusted life years (DALYs) per 100,000 inhabitants, split into Years of life lost (YLL) and Years lived with disability (YLD), by sex and age group in the European Union in 2019. The error bars indicate the 95% uncertainty interval around the DALYs estimates

Figure 1A and B show the age-standardised death and DALY rates, respectively, for the EU and each EU country in 2019, for all Level 2 causes, comparing each country with the EU. Causes had different patterns across EU countries. For example, for HIV/AIDS and sexually transmitted infections, Latvia and Portugal had the highest age-standardised death and DALY rates, with more than five times the EU. The contribution of fatal and non-fatal components of age-standardised DALY rates varied substantially across Level 2 causes (Fig. 3A). For neoplasms and cardiovascular diseases, YLLs contributed more than YLDs, while for musculoskeletal and mental disorders, the total DALYs were almost exclusively YLDs.

Figure 3B highlights the relative change in age-standardised YLL, YLD and DALY rates between 2010 and 2019 for Level 2 causes. Age-standardised YLL rates declined for all causes except for mental disorders (14.5% increase) and skin and subcutaneous diseases (2.6% increase), while Level 2 causes were quite evenly split between increases and decreases for age-standardised YLD rates. The largest decreases in age-standardised DALY rates were observed for HIV/AIDS and sexually transmitted diseases (-19.2%) and transport injuries

(-19.1%). On the other hand, only diabetes and kidney diseases showed a significant increase (3.5%) for age-standardised DALY rates in the EU between 2010 and 2019, mainly due to the age-standardised YLD rate increase. Finally, it is worth mentioning that mental disorders showed a non-significant increase for age-standardised DALY rates between 2010 and 2019 and this increase was mainly due to YLL rates, although there was also an increase in age-standardised YLD rates.

Discussion

This study presents an overview of the state of health of the EU-27 and individual Member States in 2019, comparing the findings with data from 2010 to examine changes over the last decade. The results indicate that most countries experienced a significant, albeit varied, reduction in all-cause, age-standardised mortality and YLL rates over this period, although this pattern differed by country and region. During this time period, there were no substantial changes in all-cause age-standardised YLD rates, with the increase in the Netherlands being the most notable. The EU all-cause,




Fig. 3 Age-standardised YLL, YLD and DALY rates in 2019 (A), as well as changes (in %) between 2010 and 2019 (B) for the Level 2 causes in the European Union

age-standardised DALY rate fell by 5.8% over this period, mirroring global trends [15].

The observed variability in all-cause age-standardized death rates across countries in 2019 indicates that there are geographical clusters of mortality in the EU. The pattern of mortality burden clusters with a clear geographical variation across the EU was also observed for life expectancy rates and HALE measures. This pattern has been previously highlighted [13]. However, despite recent progress to reduce these differences, its persistence suggests that improvements may not continue uniformly across the EU without enhanced, combined and coordinated efforts to address a wide range of inequalities across health determinants, including socioeconomic factors.

Neoplasms and cardiovascular diseases were the leading causes for the burden of disease in the EU in 2019; both are attributable to the behavioural risk factors and depend on early diagnosis, treatment and management of risk factors. Inherently, these are among the costliest diseases for EU countries [24]. Additionally, with population ageing, NCDs are expected to increase over time and represent a greater proportion of overall deaths with higher mortality rates associated with cancer and cardiovascular disease relative to communicable diseases [25]. A recent analysis of changes in mortality and disability, comparing data from the GBD 1990–2019, confirmed this trend, finding that there has been an overall increase in disease burden among older Europeans during this time period, primarily driven by cardiovascular diseases [26]. These changes have not been homogeneous across the EU. As structures and systems take time to adapt to such changes, it suggests that existing differences may magnify if intervention strategies are not urgently introduced.

Examining age-standardised DALY due to cancer, rates in the EU were between those of China (higher rate) and the United States of America (lower rate) [27]. EU countries had an estimated cancer burden of 4 million new cases annually in 2020, with cancer disproportionately affecting older Europeans and those living in Eastern EU Member States [28]. Future interventions must be designed to address the main drivers of NCDs, including population ageing, changes in population structure, and improvements in population-level risk factors, also considered in the Europe's Beating Cancer Plan. These must also address reasons for important differences across European regions. For example, despite the existence of cancer screening programmes across EU countries, differences in uptake of cancer screening varies according to socioeconomic factors; inequalities including lower household income, higher unemployment, and lower levels of educational attainment are associated with reduced uptake, especially in Eastern EU member states [29]. A similar trend is seen for cardiovascular diseases. EU member states with lower income levels and greater degrees of socioeconomic inequalities have disproportionately higher incidence rates and a greater burden of cardiovascular disease [30].

In this study, age-standardised death rates between countries varied widely by disease. For example, the results draw attention to the preventable high rates of self-harm and interpersonal violence across the EU in 2019. These mainly affected younger age groups. Although rates vary across the EU, we observed a geographical pattern with higher rates in the Baltic region. These differences in self-harm have been shown previously and likely relate to differences in the burden of mental disorders across the EU [31]. Baltic countries

have historically had the highest rates of alcohol-related mortality and suicide, as well as a high burden of mental and behavioural disorders [32].

Infectious diseases, in general, represented a small share of age-standardised death rates until 2019, presenting an optimistic scenario regarding these most preventable diseases. There was, however, considerable heterogeneity in age-standardised death rates for some infectious diseases such as HIV and sexually transmitted infections, which despite overall low rates, had prominent outliers with relatively high rates in Latvia and Portugal. This highlights the importance of national preventive programmes that tackle the different transmission pathways, alongside with strengthening of surveillance systems [33].

Besides this heterogeneity, such infectious diseases showed an increased age-standardised YLL rate. This will be difficult to overcome without tailored health policies as the incidence of HIV is still increasing in several EU countries [34]. Moreover, infectious diseases are likely to represent a growing share of total disease burden following the COVID-19 pandemic, and will likely be of great importance in future GBD revisions.

Regarding DALYs, remarkable regional differences were found in cardiovascular diseases, self-harm and transport injuries, which were significantly higher in Eastern EU countries. Mental disorders were the fourth highest cause of age-standardised DALY rates and did not show a decrease over recent years. In fact, they showed a non-significant increase, mainly due to a remarkable increase in YLL. These conditions also represent one of the leading causes of YLD, which has been rising over recent years and has increased even more following the COVID-19 pandemic [35, 36]. Additionally, self-harm and interpersonal violence may also be linked to mental disorders, as an example of interacting causes. Thus, viewed as a whole, mental health disorders and other related possible outcomes such as self-harm and mortality linked to mental disorders, deserve special attention in line with WHO priorities [37].

The age-standardised YLD estimates generated by the GBD 2019 study show slight variation over time and across geographic areas and are subject to large levels of uncertainty. The former is mainly driven by the fact that the GBD severity distributions do not vary over time and space [38], essentially reducing differences in YLD rates to differences in the underlying prevalence estimates. Since prevalence data are typically sparser and more uncertain than mortality data, the modelled prevalence estimates further tend to smooth out temporal and spatial heterogeneity. In parallel, EU countries would need to improve the quality and performance of their health information systems, strengthening and integrating data

available through disease registers, claims data, primary care data, hospital discharge data and health surveys.

Strengths and limitations

This study is important and timely as it reflects the state of health in the EU prior to a number of major changes, including the COVID-19 pandemic and Brexit (the departure of the UK from the EU), and therefore will likely be important for policy-makers to understand the state of health of Europe at this pivotal moment in time. Although the UK is not included in the analysis and that potential adverse effects of Brexit on the health of the UK have been discussed [39], less is known about how it could impact the remaining EU-27. To date, there has been wide variation in the resilience and responses of health systems and governments to the pandemic across the EU, which replicates many of the regional variations presented in this study of the state of health of the EU. Comparing the results of this study with post-pandemic and post-Brexit GBD data will therefore be crucial to assess the impact of these 'shocks' on the health of EU citizens. Moreover, it could be pivotal for policy makers to address in future studies. Another strength of this study is that it provides estimates at the national level for EU countries for which burden of disease studies are lacking or are scarce and can support priority setting and resource allocations. This study used estimates provided by the GBD 2019 study and hence shares some limitations with other GBD studies, predominantly related mostly to the availability and quality of primary data, in particular for morbidity, which might not be homogeneous across EU countries. Moreover, there are some limitations pertaining to this paper related to: (1) the study design as it is a descriptive study, does not aim to estimate the effect of EU level policies; (2) timeline (as it provides an overall EU-level assessment across 10 years and excludes in-depth national assessment taking into account the year of accession to the EU); and (3) data availability. In addition, GBD metrics apply the same disability weights for all countries and regions. Such limitations have been widely discussed in the literature [15, 38].

Regarding the age-standardisation, it is also essential to highlight that while it is essential to ensure a global and comparable age standardisation, the used world standard population by GBD instead of a European standard population may change the ranking of causes [40].

Conclusions

In conclusion, although population health in the EU has been improving, large differences between countries persist. Health outcomes remain much better in Western or Southern Europe (e.g. Spain, Italy or France) than in Central and Eastern Europe (e.g. Bulgaria or Romania)

or the Baltic states (e.g. Latvia or Lithuania). NCDs, particularly neoplasms and cardiovascular diseases continue to be the leading causes of disease burden. This study suggests that addressing the prevalence and incidence of diseases and injuries should be a priority for EU health policy makers, emphasising reducing health inequalities across the block. Attention must be paid to specific causes, including mental disorders, given their impact on YLD [41]. This study highlights that there are many opportunities for mutual learning among otherwise similar EU countries with different patterns of disease and injury.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12889-024-18529-3>.

Supplementary Material 1.

Acknowledgements

The authors would like to acknowledge the networking support from COST Action CA18218 (European Burden of Disease Network), supported by COST (European Cooperation in Science and Technology). This article was supported by National Funds through FCT - Fundação para a Ciência e a Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).

GBD 2019 EU State of Health Collaborators

João Vasco Santos, MD,^{1,2} Alicia Padron-Monedero, PhD,³ Boris Bikbov, MD,⁴ Diana Alecsandra Grad, BA,^{5,6} Dietrich Plass, DrPH,⁷ Enkeleint A Mechili, PhD,^{8,9} Federica Gazzelloni, BSc,¹⁰ Florian Fischer, PhD,¹¹ Gerhard Sulo, PhD,¹² Che Henry Ngwa, MSc,¹³ Prof Isabel Nogueira-Zambrano, PhD,³ Prof José L Peñalvo, PhD,^{14,15} Juanita A Haagsma, PhD,¹⁶ Katarzyna Kissimova-Skarbek, PhD,¹⁷ Lorenzo Monasta, DSc,¹⁸ Nermin Ghith, PhD,¹⁹ Prof Rodrigo Sarmiento-Suárez, MPH,^{20,3} Rok Hrzic, MSc,²¹ Romana Haneef, PhD,²² Rónán O'Caomh, PhD,^{23,24} Sarah Cuschieri, PhD,²⁵ Prof Stefania Mondello, NA,²⁶ Zubair Kabir, PhD,²⁷ Cristiana Abbafati, PhD,²⁸ Hassan Abolhassani, PhD,^{29,30} Victor Adekanmbi, PhD,³¹ Keivan Ahmadi, PhD,³² Sepideh Ahmadi, PhD,³³ Prof Adel Al-Jumaily, PhD,^{34,35} Prof François Alla, PhD,³⁶ Jordi Alonso, MD,^{37,38} Prof Robert Ancuceanu, PhD,³⁹ Catalina Liliana Andrei, PhD,⁴⁰ Prof Tudorel Andrei, PhD,⁴¹ Sofia Androudi, PhD,⁴² Prof Josep M Antó, MD,^{43,44} Seth Christopher Yaw Appiah, PhD,^{45,46} Olatunde Aremu, PhD,⁴⁷ Benedetta Armocida, MSc,⁴⁸ Prof Johan Årnlöv, PhD,^{49,50} Ashokan Arumugam, PhD,^{51,52} Sameh Attia, MSc,⁵³ Avinash Aujayeb, MBS, PhD,⁵⁴ Prof Marcel Ausloos, PhD,^{55,41} Prof Jose L Ayuso-Mateos, PhD,^{56,57} Prof Maciej Banach, PhD,^{58,59} Prof Till Winfried Bärnighausen, MD,^{60,61} Francesco Barone-Adesi, PhD,⁶² Sandra Barteit, PhD,⁶³ Sanjay Basu, PhD,^{64,32} Prof Bernhard T Baune, PhD,^{65,66} Massimiliano Beghi, MD,⁶⁷ Luis Belo, PhD,^{68,69} Derrick A Bennett, PhD,⁷⁰ Prof Antonio Biondi, PhD,⁷¹ Mahdi Bohluli, PhD,^{72,73} Israel Júnior Borges do Nascimento, MD,^{74,75} Nicola Luigi Bragazzi, PhD,⁷⁶ Tasanee Braithwaite, PhD,^{77,78} Prof Hermann Brenner, MD,⁷⁹ Danilo Buonsenso, MD,^{80,81} Prof Reinhard Busse, PhD,⁸² Prof Daniela Calina, PhD,⁸³ Giulia Carreras, PhD,⁸⁴ Mária Carvalho, PhD,^{85,69} Giulio Castelpietra, PhD,^{86,87} Prof Alberico L Catapano, PhD,^{88,89} Maria Sofia Cattaruzza, PhD,⁹⁰ Joht Singh Chandan, MFPH,⁹¹ Periklis Charalampous, MSc,¹⁶ Vijay Kumar Chattu, MD,^{92,93} Simiao Chen, DSc,⁶⁰ Prof Rajiv Chowdhury, PhD,^{94,95} Prof Hanne Christensen, DMSci,⁹⁶ Sheng-Chia Chung, PhD,^{97,98} Joao Conde, PhD,⁹⁹ Barbara Corso, PhD,¹⁰⁰ Prof Natália Cruz-Martins, PhD,^{101,102} Giovanni Damiani, MD,^{103,104} Alejandro de la Torre-Luque, PhD,¹⁰⁵ Andreas K Demetriades, MD,^{106,107} Nikolaos Dervenis, MD,^{108,109} Mostafa Dianatinasab, MSc,^{110,111} Prof Diana Dias da Silva, PhD,^{112,69} Abdel Douiri, PhD,¹¹³ Prof David Edvardsson, PhD,^{114,115} Luchuo Engelbert Bain, PhD,¹¹⁶ Francesco Esposito, MD,¹¹⁷ Adeniyi Francis Fagbamigbe, PhD,^{118,119} Carla Sofia e Sá Farinha, MSc,^{120,121} Seyed-Mohammad Fereshtehnejad, PhD,^{49,122} João C Fernandes, PhD,¹²³ Pietro Ferrara, MD,¹²⁴ Peter Andras Gaal, PhD,^{125,126} Silvano Gallus, DSc,¹²⁷ Lucia Galluzzo, MA,⁴⁸ Mariana Gaspar Fonseca, PhD,¹²⁸ Prof Gus Gazzard, MD,^{129,130} Alessandro Gialluisi, PhD,¹³¹ Simona Giampaoli, MD,¹³² Prof Paramjit Singh Gill, DM,¹³³ James C

Glasbey, MSc,¹³⁴ Giuseppe Gorini, MD,¹³⁵ Prof Michal Grivna, PhD,^{136,137} Abdul Hafiz, PhD,^{138,139} Josep Maria Haro, MD,^{140,141} Prof Jan Hartvigsen, PhD,^{142,143} Prof Simon I Hay, FMedSci,^{144,145} Behzad Heibati, PhD,¹⁴⁶ David Hillus, MD,¹⁴⁷ Mehdi Hosseinzadeh, PhD,^{148,149} Mihaela Hostiuc, PhD,¹⁵⁰ Sorin Hostiuc, PhD,^{151,152} Salman Hussain, PhD,^{153,154} Prof Gaetano Isola, PhD,¹⁵⁵ Olatunji Johnson, PhD,¹⁵⁶ Prof Jost B Jonas, MD,^{157,158} Tamas Joo, PhD,^{125,159} Jacek Jerzy Jozwiak, PhD,¹⁶⁰ Mikko Jürisson, PhD,¹⁶¹ Marina Karanikolos, PhD,^{162,163} Joonas H Kauppila, MD,^{164,165} Moien AB Khan, MSc,^{166,167} Khaled Khatib, PhD,^{168,169} Miloslav Klugar, PhD,^{153,170} Ai Koyanagi, MD,^{171,172} Om P Kurmi, PhD,^{173,174} Dian Kusuma, DSc,^{175,176} Prof Carlo La Vecchia, MD,¹⁷⁷ Ben Lacey, PhD,^{70,178} Demetris Lamnisos, PhD,¹⁷⁹ Prof Heidi Jane Larson, PhD,^{180,144} Prof Anders O Larsson, PhD,^{181,182} Savita Lasrado, MS,¹⁸³ Paolo Lauriola, MD,¹⁸⁴ Prof Jeffrey V Lazarus, PhD,¹⁸⁵ Caterina Ledda, PhD,¹⁸⁶ Paul H Lee, PhD,¹⁸⁷ Mall Leinsalu, PhD,^{188,189} Matilde Leonardi, MD,¹⁹⁰ Miriam Levi, PhD,^{191,192} An Li, PhD,^{193,194} Christine Linehan, PhD,¹⁹⁵ Prof Giancarlo Logroscino, PhD,^{196,197} Prof Stefan Lorkowski, PhD,^{198,199} Joana A Loureiro, PhD,^{200,201} Prof Ronan A Lyons, MD,²⁰² Áurea M Madureira-Carvalho, PhD,^{112,203} Prof Azeem Majeed, MD,²⁰⁴ Alexander G Mathioudakis, PhD,^{205,206} Colm McAlinden, PhD,²⁰⁷ Prof John J McGrath, MD,^{208,209} Prof Ritesh G Menezes, MD,²¹⁰ Alexios-Fotios A Mentis, MD,²¹¹ Atte Meretoja, MD,^{212,213} Tuomo J Meretoja, MD,^{214,215} Tomislav Mestrovic, PhD,^{216,144} Junmei Miao Jonasson, PhD,²¹⁷ Bartosz Miazgowski, MD,^{218,219} Prof Tomasz Miazgowski, MD,²²⁰ Andreea Mirica, PhD,⁴¹ Shafiq Mohammed, PhD,^{221,82} Ali H Mokdad, PhD,^{144,145} Prof Ute Mons, PhD,²²² Joana Morgado-Costa, MSc,²²³ Francesk Mulita, PhD,^{224,225} Prof Christopher J L Murray, DPhil,^{144,145} Ionut Negoii, PhD,^{226,227} Ruxandra Irina Negoii, PhD,^{228,229} Serban Mircea Negru, MD,²³⁰ Evangelia Nena, MD,²³¹ Nurulamin M Noor, MRCp,^{232,233} George Ntaios, PhD,²³⁴ Prof Bogdan Oancea, PhD,²³⁵ Frank B Osei, PhD,^{236,237} Adrian Otoiui, PhD,⁴¹ Raffaele Palladino, MD,^{238,204} Songhomitra Panda-Jonas, MD,²³⁹ Prof Shahina Pardhan, PhD,²⁴⁰ Jay Patel, NA,^{241,242} Prof Mihaela Paun, PhD,^{243,244} Paolo Pedersini, MSc,²⁴⁵ Umberto Pensato, MD,²⁴⁶ Renato B Pereira, PhD,²⁴⁷ Prof Jorge Pérez-Gómez, PhD,²⁴⁸ Norberto Perico, MD,²⁴⁹ Ionela-Roxana Petcu, PhD,⁴¹ Carrie B Peterson, PhD,²⁵⁰ Marina Pinheiro, PhD,²⁴⁷ Prof Maarten J Postma, PhD,^{251,252} Alberto Raggi, PhD,¹⁹⁰ Amir Masoud Rahmani, PhD,²⁵³ Chythra R Rao, MD,²⁵⁴ Prof Salman Rawaf, MD,^{204,255} Reza Rawassizadeh, PhD,²⁵⁶ Prof Giuseppe Remuzzi, MD,²⁴⁹ Anaboub Riad, DDS,^{257,153} Prof Simona Sacco, MD,²⁵⁸ Prof Mohammad Reza Saeb, PhD,²⁵⁹ Brijesh Sathian, PhD,^{260,261} Davide Sattin, PsyD,²⁶² Prof Nikolaos Scarmeas, PhD,^{263,264} Prof Falk Schwendicke, PhD,²⁶⁵ Rahman Shiri, PhD,²⁶⁶ Velizar Shivarov, PhD,^{267,268} Kibrom T Sibhatu, PhD,²⁶⁹ Prof Biagio Simonetti, PhD,^{270,271} Prof Søren T Skou, PhD,^{142,272} Prof Joan B Soriano, MD,^{273,274} Ireneous N Soyiri, PhD,²⁷⁵ Prof Nicholas Steel, PhD,^{276,277} Simona Cătălina Ștefan, PhD,²⁷⁸ Fridolin Steinbeis, MD,¹⁴⁷ Paschalis Steiropoulos, MD,²³¹ Leo Stockfelt, PhD,²⁷⁹ Prof Saverio Stranges, MD,^{280,281} Prof Johan Sundström, PhD,^{181,282} Prof Rafael Tabarés-Seisdedos, PhD,^{283,284} Arulmani Thiyagarajan, MPH,²⁸⁵ Roman Topor-Madry, PhD,^{286,287} Marcos Roberto Tovani-Palone, PhD,^{288,289} Nikolaos Tsilimparis, PhD,²⁹⁰ Brigid Unim, PhD,⁴⁸ Marco Vacante, PhD,⁷¹ Jef Van den Eynde, BSc,²⁹¹ Prof Tommi Juhani Vasankari, MD,^{292,293} Prof Massimiliano Veroux, PhD,²⁹⁴ Jorge Hugo Villafañe, PhD,²⁴⁵ Prof Francesco S Violante, MD,^{295,296} Yanzhong Wang, PhD,¹¹³ Ronny Westerman, DSc,²⁹⁷ Prof Charles D A Wolfe, MD,^{113,298} Grant M A Wyper, MSc,²⁹⁹ Prof Sanni Yaya, PhD,^{300,301} Prof Vesna Zadnik, PhD,³⁰² Jean-David Zeitoun, PhD,^{303,304} Prof Alimuddin Zumla, PhD,^{305,306} Alberto Freitas, PhD,^{307,1} Prof. Brecht Devleeschauwer, PhD.^{308,309}

Affiliations

¹CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal; ²Public Health Unit, ULS Santo António, Porto, Portugal; ³National School of Public Health, Institute of Health Carlos III, Madrid, Spain; ⁴Scientific-Tools.Org, Bergamo, Italy; ⁵Research Department, RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania; ⁶Department of Public Health, Babes-Bolyai University, Cluj-Napoca, Romania; ⁷Department for Exposure Assessment and Environmental Health Indicators, German Environment Agency, Dessau-Roßlau, Germany; ⁸Department of Healthcare, University of Vlora, Vlora, Albania; ⁹Clinic of Social and Family Medicine, University of Crete, Heraklion, Greece; ¹⁰Independent researcher; ¹¹Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany; ¹²Department of Disease Burden, Norwegian Institute of Public Health, Bergen, Norway; ¹³Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon; ¹⁴National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; ¹⁵The Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University,

Boston, MA, USA; ¹⁶Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands; ¹⁷Department of Health Economics and Social Security, Jagiellonian University Medical College, Krakow, Poland; ¹⁸Clinical Epidemiology and Public Health Research Unit, Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; ¹⁹Research group for Childhood Cancer, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark; ²⁰Department of Health and Society, Faculty of Medicine, University of Applied and Environmental Sciences, Bogota, Colombia; ²¹Department of International Health, Maastricht University, Maastricht, Netherlands; ²²Department of Non-communicable Diseases and Injuries, Santé Publique France (Public Health France), Saint-Maurice, France; ²³Department of Medicine, University College Cork, Cork, Ireland; ²⁴Department of Geriatric Medicine, Mercy University Hospital, Cork, Ireland; ²⁵Anatomy Department, University of Malta, Msida, Malta; ²⁶Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina University, Messina, Italy; ²⁷School of Public Health, University College Cork, Cork, Ireland; ²⁸Department of Juridical and Economic Studies, La Sapienza University, Rome, Italy; ²⁹Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran; ³⁰Department of Biosciences and Nutrition, Karolinska University Hospital, Huddinge, Sweden; ³¹Department of Obstetrics & Gynecology, University of Texas, Galveston, TX, USA; ³²School of Public Health, Imperial College London, London, UK; ³³School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ³⁴School of Computing, Mathematics and Engineering, Charles Sturt University, Wagga Wagga, NSW, Australia; ³⁵Information and Communication Sciences and Technologies Pole, Mathematics, Algorithms and Decision Team, ENSTA Bretagne, Brest, France; ³⁶Bordeaux School of Public Health, University of Bordeaux, Bordeaux, France; ³⁷Research Program of Epidemiology and Public Health, Pompeu Fabra University, Barcelona, Spain; ³⁸Department of Experimental and Health Sciences, Biomedical Research Networking Center in Epidemiology and Public Health (CiberESP), Madrid, Spain; ³⁹Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁴⁰Cardiology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ⁴¹Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania; ⁴²Department of Medicine, University of Thessaly, Volos, Greece; ⁴³Non-Communicable Diseases & Environment Programme, Barcelona Institute for Global Health, Barcelona, Spain; ⁴⁴Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain; ⁴⁵Department of Sociology and Social Work, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; ⁴⁶Center for International Health, Ludwig Maximilians University, Munich, Germany; ⁴⁷Department of Public Health, Birmingham City University, Birmingham, UK; ⁴⁸Department of Cardiovascular, Endocrine-metabolic Diseases and Aging, National Institute of Health, Rome, Italy; ⁴⁹Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden; ⁵⁰School of Health and Social Studies, Dalarna University, Falun, Sweden; ⁵¹Department of Physiotherapy, University of Sharjah, Sharjah, United Arab Emirates; ⁵²Department Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden; ⁵³Oral and Maxillofacial Surgery, Justus Liebig University of Giessen, Giessen, Germany; ⁵⁴Northumbria HealthCare NHS Foundation Trust, National Health Service (NHS) Scotland, Newcastle upon Tyne, UK; ⁵⁵School of Business, University of Leicester, Leicester, UK; ⁵⁶Department of Psychiatry, Autonomous University of Madrid (Universidad Autónoma de Madrid), Madrid, Spain; ⁵⁷CIBERSAM, Institute of Health Carlos III, Madrid, Spain; ⁵⁸Department of Hypertension, Medical University of Lodz, Lodz, Poland; ⁵⁹Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland; ⁶⁰Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany; ⁶¹T.H. Chan School of Public Health, Harvard University, Boston, MA, USA; ⁶²Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; ⁶³Heidelberg Institute of Global Health (HIGH), Heidelberg University Hospital, Heidelberg, Germany; ⁶⁴Center for Primary Care, Harvard University, Boston, MA, USA; ⁶⁵Department of Psychiatry, University of Münster, Münster, Germany; ⁶⁶Department of Psychiatry, Melbourne Medical School, Melbourne, VIC, Australia; ⁶⁷Department of Mental Health, AUSL Romagna, Ravenna, Italy; ⁶⁸Biological Sciences Department, University of Porto, Porto, Portugal; ⁶⁹Research Unit on Applied Molecular Biosciences (UCIBIO), University of Porto, Porto, Portugal; ⁷⁰Nuffield Department of Population Health, University of Oxford, Oxford, UK; ⁷¹Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy; ⁷²Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences, Zanjan, Iran; ⁷³Department of Research and Innovation, Petanux Research GmbH, Bonn, Germany; ⁷⁴School of Medicine and University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil; ⁷⁵Division of Country Health Policies and Systems, World Health Organization (WHO), Denmark, Denmark; ⁷⁶University of Genoa, Genoa, Italy; ⁷⁷Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK; ⁷⁸International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, UK; ⁷⁹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; ⁸⁰Department of Woman and Child Health and Public Health, Agostino Gemelli University Polyclinic IRCCS (Fondazione Policlinico Universitario A. Gemelli IRCCS), Roma, Italy; ⁸¹Global Health Research Institute, Università Cattolica del Sacro Cuore (Catholic University of Sacred Heart), Roma, Italy; ⁸²Department of Health Care Management, Technical University of Berlin, Berlin, Germany; ⁸³Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Romania, Craiova, Romania; ⁸⁴Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ⁸⁵Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal; ⁸⁶Department of Medicine, University of Udine, Udine, Italy; ⁸⁷Department of Mental Health, Healthcare Agency "Friuli Occidentale", Pordenone, Italy; ⁸⁸Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy; ⁸⁹MultiMedica, IRCCS, Sesto S. Giovanni, Italy; ⁹⁰Department of Public Health and Infectious Diseases, La Sapienza University, Rome, Italy; ⁹¹Institute of Applied Health Research, University of Birmingham, Birmingham, UK; ⁹²Faculty of Medical Sciences, University of the West Indies, St Augustine, Trinidad and Tobago; ⁹³Independent Consultant, Athens, Greece; ⁹⁴Florida International University, Florida International University, Miami, FL, USA; ⁹⁵Department of Epidemiology, University of Bern, Bern, Switzerland; ⁹⁶Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; ⁹⁷Department of Health Informatics, University College London, London, UK; ⁹⁸Health Data Research UK, London, UK; ⁹⁹Nova Medical School, Nova University of Lisbon, Lisbon, Portugal; ¹⁰⁰Institute of Neuroscience, National Research Council, Pisa, Italy; ¹⁰¹Therapeutic and Diagnostic Technologies, Cooperativa de Ensino Superior Politécnico e Universitário (Polytechnic and University Higher Education Cooperative), Gandra, Portugal; ¹⁰²Institute for Research and Innovation in Health, University of Porto, Porto, Portugal; ¹⁰³IRCCS Istituto Ortopedico Galeazzi (Galeazzi Orthopedic Institute IRCCS), University of Milan, Milan, Italy; ¹⁰⁴Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA; ¹⁰⁵Department of Legal Medicine, Psychiatry and Pathology, Complutense University of Madrid (Universidad Complutense de Madrid), Madrid, Spain; ¹⁰⁶Department of Neurosurgery, University of Edinburgh, Edinburgh, UK; ¹⁰⁷Department of Neurosurgery, National Health Service (NHS) Scotland, Edinburgh, UK; ¹⁰⁸St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK; ¹⁰⁹Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ¹¹⁰Department of Epidemiology, Maastricht University, Maastricht, Netherlands; ¹¹¹Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran; ¹¹²Toxicology Research Unit (TOXRUN), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU) (University Polytechnic Higher Education Cooperative), Gandra, Portugal; ¹¹³School of Population Health and Environmental Sciences, King's College London, London, UK; ¹¹⁴School of Nursing and Midwifery, La Trobe University, Melbourne, VIC, Australia; ¹¹⁵Department of Nursing, Umeå University, Umeå, Sweden; ¹¹⁶Lincoln International Institute for Rural Health, University of Lincoln, Lincoln, UK; ¹¹⁷Dipartimento di Scienze Biomediche e Neuromotorie (Department of Biomedical and Neuromotor Sciences), University of Bologna, Bologna, Italy; ¹¹⁸Department of Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria; ¹¹⁹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; ¹²⁰Dissemination Division, National Institute of Statistics, Lisbon, Portugal; ¹²¹Activity Planning and Control Unit, Directorate-General of Health (DGS), Lisbon, Portugal; ¹²²Division of Neurology, University of Ottawa, Ottawa, ON, Canada; ¹²³Center for Biotechnology and Fine Chemistry, Catholic University of Portugal, Porto, Portugal; ¹²⁴Research Center on Public Health, University of Milan Bicocca, Monza, Italy; ¹²⁵Health Services Management Training Centre, Semmelweis University, Budapest, Hungary; ¹²⁶Department of Applied Social Sciences, Sapientia Hungarian University of Transylvania, Târgu-Mureş, Romania; ¹²⁷Department of Environmental Health Sciences, Mario Negri Institute for Pharmacological Research, Milan, Italy; ¹²⁸National Health Service, London, UK; ¹²⁹Institute of Ophthalmology, University College London, London, UK; ¹³⁰Moorfields Eye Hospital NHS Foundation Trust, London, UK; ¹³¹Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, Italy; ¹³²Department of Cardiovascular Endocrine-metabolic Diseases and Aging, Istituto

Superiore di Sanità, Rome, Italy; ¹³³Warwick Medical School, University of Warwick, Coventry, UK; ¹³⁴NHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK; ¹³⁵Oncological Network, Prevention and Research Institute, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy; ¹³⁶College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates; ¹³⁷Department of Public Health and Preventive Medicine, Charles University, Prague, Czech Republic; ¹³⁸College of Medicine, Umm AL Qura University, Makkah, Saudi Arabia; ¹³⁹MSc Epidemiology Programme, London School of Hygiene & Tropical Medicine, London, UK; ¹⁴⁰Research Unit, University of Barcelona, Barcelona, Spain; ¹⁴¹Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, Spain; ¹⁴²Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; ¹⁴³Research Department, Nordic Institute of Chiropractic and Clinical Biomechanics, Odense, Denmark; ¹⁴⁴Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; ¹⁴⁵Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA; ¹⁴⁶Research Unit of Population Health, University of Oulu, Oulu, Finland; ¹⁴⁷Department of Infectious Diseases and Respiratory Medicine, Charité Medical University Berlin, Berlin, Germany; ¹⁴⁸Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam; ¹⁴⁹Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq; ¹⁵⁰Internal Medicine Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ¹⁵¹Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ¹⁵²Clinical Legal Medicine Department, National Institute of Legal Medicine Mina Minovici, Bucharest, Romania; ¹⁵³Czech National Centre for Evidence-based Healthcare and Knowledge Translation, Masaryk University, Brno, Czech Republic; ¹⁵⁴Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; ¹⁵⁵Department of General Surgery and Surgical-Medical Specialties, University of Catania, Catania, Italy; ¹⁵⁶Department of Mathematics, University of Manchester, Manchester, UK; ¹⁵⁷Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland; ¹⁵⁸Department of Ophthalmology, Heidelberg University, Mannheim, Germany; ¹⁵⁹Hungarian Health Management Association, Budapest, Hungary; ¹⁶⁰Department of Family Medicine and Public Health, University of Opole, Opole, Poland; ¹⁶¹Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia; ¹⁶²European Observatory on Health Systems and Policies, London School of Hygiene & Tropical Medicine, London, UK; ¹⁶³Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; ¹⁶⁴Surgery Research Unit, University of Oulu, Oulu, Finland; ¹⁶⁵Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; ¹⁶⁶Family Medicine Department, United Arab Emirates University, Al Ain, United Arab Emirates; ¹⁶⁷Primary Care Department, NHS North West London, London, UK; ¹⁶⁸Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK; ¹⁶⁹College of Arts and Sciences, Ohio University, Zanesville, OH, USA; ¹⁷⁰Institute for Health Information and Statistics of the Czech Republic, Prague, Czech Republic; ¹⁷¹Biomedical Research Networking Center for Mental Health Network (CIBERSAM), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; ¹⁷²Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; ¹⁷³Faculty of Health and Life Sciences, Coventry University, Coventry, UK; ¹⁷⁴Department of Medicine, McMaster University, Hamilton, ON, Canada; ¹⁷⁵Department of Health Services Research and Management, City University of London, London, UK; ¹⁷⁶Faculty of Public Health, University of Indonesia, Depok, Indonesia; ¹⁷⁷Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; ¹⁷⁸National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK; ¹⁷⁹Department of Health Sciences, European University Cyprus, Nicosia, Cyprus; ¹⁸⁰Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; ¹⁸¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ¹⁸²Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Uppsala, Sweden; ¹⁸³Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India; ¹⁸⁴International Society Doctors for the Environment, Arezzo, Italy; ¹⁸⁵Barcelona Institute for Global Health, Barcelona, Spain; ¹⁸⁶Clinical and Experimental Medicine, University of Catania, Catania, Italy; ¹⁸⁷Department of Health Sciences, University of Leicester, Leicester, UK; ¹⁸⁸School of Social Sciences, Södertörn University, Huddinge, Sweden; ¹⁸⁹Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia; ¹⁹⁰UO Neurologia, Salute Pubblica e Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta (Neurology, Public Health and Disability Unit, Carlo Besta Neurological Institute), Milan, Italy; ¹⁹¹Department of Prevention, USL Tuscany Center, Firenze, Italy; ¹⁹²Department of Health Sciences, University of Florence, Florence, Italy; ¹⁹³Center for Dentistry and Oral Hygiene, University of Groningen, Groningen, Netherlands; ¹⁹⁴Stomatological Hospital, Southern Medical University, Guangzhou, China; ¹⁹⁵UCD Centre for Disability Studies, University College Dublin, Dublin, Ireland; ¹⁹⁶Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy; ¹⁹⁷Department of Clinical Research in Neurology, Fondazione Cardinale Giovanni Panico Hospital, Tricase, Italy; ¹⁹⁸Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany; ¹⁹⁹Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany; ²⁰⁰Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), University of Porto, Porto, Portugal; ²⁰¹School of Health, Polytechnic Institute of Porto, Portugal; ²⁰²School of Medicine, Swansea University, Swansea, UK; ²⁰³Laboratório de Farmacognosia (LAQV) (Associated Laboratory for Green Chemistry, University of Porto, Porto, Portugal; ²⁰⁴Department of Primary Care and Public Health, Imperial College London, London, UK; ²⁰⁵Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK; ²⁰⁶North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK; ²⁰⁷Department of Ophthalmology, Singleton Hospital, Swansea, UK; ²⁰⁸Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia; ²⁰⁹National Centre for Register-based Research, Aarhus University, Aarhus, Denmark; ²¹⁰Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; ²¹¹International Dx Department, BGI Genomics, Copenhagen, Denmark; ²¹²Neurology Unit, Helsinki University Hospital, Helsinki, Finland; ²¹³School of Health Sciences, University of Melbourne, Melbourne, VIC, Australia; ²¹⁴Breast Surgery Unit, Helsinki University Hospital, Helsinki, Finland; ²¹⁵University of Helsinki, Helsinki, Finland; ²¹⁶University Centre Varazdin, University North, Varazdin, Croatia; ²¹⁷School of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden; ²¹⁸Center for Innovation in Medical Education, Pomeranian Medical University, Szczecin, Poland; ²¹⁹Pomeranian Medical University, Szczecin, Poland; ²²⁰Department of Propedeutics of Internal Diseases & Arterial Hypertension, Pomeranian Medical University, Szczecin, Poland; ²²¹Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria; ²²²Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; ²²³University Hospital Center of Porto, University of Porto, Porto, Portugal; ²²⁴Department of Surgery, General University Hospital of Patras, Patras, Greece; ²²⁵Medical School, University of Thessaly, Larissa, Greece; ²²⁶Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ²²⁷Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania; ²²⁸Department of Anatomy and Embryology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ²²⁹Department of Cardiology, Cardio-Aid, Bucharest, Romania; ²³⁰Department of Oncology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania; ²³¹Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece; ²³²Medical Research Council Clinical Trials Unit, University College London, London, UK; ²³³Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK; ²³⁴Department of Internal Medicine, University of Thessaly, Larissa, Greece; ²³⁵Department of Applied Economics and Quantitative Analysis, University of Bucharest, Bucharest, Romania; ²³⁶Faculty of Geo-Information Science and Earth Observation, University of Twente, Enschede, Netherlands; ²³⁷Department of Mathematics and Statistics, University of Energy and Natural Resources, Sunyani, Ghana; ²³⁸Department of Public Health, University of Naples Federico II, Naples, Italy; ²³⁹Privatpraxis, Heidelberg, Germany; ²⁴⁰Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK; ²⁴¹Global Health Governance Programme, University of Edinburgh, Edinburgh, UK; ²⁴²School of Dentistry, University of Leeds, Leeds, UK; ²⁴³Department of Bioinformatics and Biostatistics, National Institute of Research and Development for Biological Sciences, Bucharest, Romania; ²⁴⁴Department of Statistics and Cybernetics, University of Bucharest, Bucharest, Romania; ²⁴⁵Clinical Research Department, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy; ²⁴⁶Department of Neurology, IRCCS Humanitas Research Hospital, Milan, Italy; ²⁴⁷Department of Chemistry, University of Porto, Porto, Portugal; ²⁴⁸Departamento de Didáctica de la Expresión Musical, Plástica y Corporal, University of Extremadura, Cáceres, Spain; ²⁴⁹Mario Negri Institute for Pharmacological Research, Bergamo, Italy; ²⁵⁰Independent Consultant, Copenhagen, Denmark; ²⁵¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands; ²⁵²Center of Excellence in

Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran (Padjadjaran University), Bandung, Indonesia; ²⁵³Future Technology Research Center, National Yunlin University of Science and Technology, Yunlin, Taiwan; ²⁵⁴Department of Community Medicine, Manipal Academy of Higher Education, Manipal, India; ²⁵⁵Academic Public Health England, Public Health England, London, UK; ²⁵⁶Department of Computer Science, Boston University, Boston, MA, USA; ²⁵⁷Department of Public Health, Masaryk University, Brno, Czech Republic; ²⁵⁸Department of Neurology, University of L'Aquila, L'Aquila, Italy; ²⁵⁹Department of Polymer Technology, Independent Consultant, Gdansk, Poland; ²⁶⁰Geriatric and Long Term Care Department, Hamad Medical Corporation, Doha, Qatar; ²⁶¹Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK; ²⁶²IRCCS Istituti Clinici Scientifici Maugeri (IRCCS Maugeri Scientific Clinical Institute), Milan, Italy; ²⁶³Department of Neurology, National and Kapodistrian University of Athens, Athens, Greece; ²⁶⁴Department of Neurology, Columbia University, New York, NY, USA; ²⁶⁵Oral Diagnosis, Digital Health and Health Services Research, Charité University Medical Center Berlin, Berlin, Germany; ²⁶⁶Finnish Institute of Occupational Health, Helsinki, Finland; ²⁶⁷Clinical Immunology and Hematology, Sofamed University Hospital, Sofia, Bulgaria; ²⁶⁸Department of Genetics, Sofia University "St. Kliment Ohridski", Sofia, Bulgaria; ²⁶⁹Department of Agricultural Economics and Rural Development, University of Göttingen, Göttingen, Germany; ²⁷⁰Department of Law, Economics, Management and Quantitative Methods, University of Sannio, Benevento, Italy; ²⁷¹WSB University in Gdańsk, Gdańsk, Poland; ²⁷²Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Slagelse, Denmark; ²⁷³Hospital Universitario de La Princesa (Princess University Hospital), Autonomous University of Madrid, Madrid, Spain; ²⁷⁴Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES) (Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain; ²⁷⁵Hull York Medical School, University of Hull, Hull City, UK; ²⁷⁶Department of Primary Care and Public Health, University of East Anglia, Norwich, UK; ²⁷⁷Public Health England, London, UK; ²⁷⁸Management Department, Bucharest University of Economic Studies, Bucharest, Romania; ²⁷⁹Occupational and Environmental Medicine Department, University of Gothenburg, Gothenburg, Sweden; ²⁸⁰Department of Epidemiology & Biostatistics, The University of Western Ontario, London, ON, Canada; ²⁸¹Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg; ²⁸²The George Institute for Global Health, Sydney, NSW, Australia; ²⁸³Department of Medicine, University of Valencia, Valencia, Spain; ²⁸⁴Institute of Health Carlos III, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain; ²⁸⁵Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology, Bremen, Germany; ²⁸⁶Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland; ²⁸⁷Agency for Health Technology Assessment and Tariff System, Warsaw, Poland; ²⁸⁸Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India; ²⁸⁹Modestum LTD, Eastbourne, UK; ²⁹⁰Department of Vascular Surgery, Ludwig Maximilians University, Munich, Germany; ²⁹¹Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, Leuven, Belgium; ²⁹²UKK Institute, Tampere, Finland; ²⁹³Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ²⁹⁴Department of Medical and Surgical Sciences and Advanced Technologies, University of Catania, Catania, Italy; ²⁹⁵Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; ²⁹⁶Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy; ²⁹⁷Competence Center of Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany; ²⁹⁸NIHR-Biomedical Research Centre (NIHR-BRC), Guy's and St. Thomas' Hospital and Kings College London, London, UK; ²⁹⁹School of Health and Wellbeing, University of Glasgow, Glasgow, UK; ³⁰⁰School of International Development and Global Studies, University of Ottawa, Ottawa, ON, Canada; ³⁰¹The George Institute for Global Health, Imperial College London, London, UK; ³⁰²Epidemiology and Cancer Registry Sector, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ³⁰³Centre of Clinical Epidemiology, Hôtel Dieu Hospital, Assistance Publique Hôpitaux de Paris (Public Hospitals of Paris), Paris, France; ³⁰⁴Gastroenterology and Nutrition, Saint-Antoine Hospital, Assistance Publique Hôpitaux de Paris (Public Hospitals of Paris), Paris, France; ³⁰⁵Department of Infection, University College London, London, UK; ³⁰⁶NIHR-Biomedical Research Centre (NIHR-BRC), University College London Hospitals, London, UK; ³⁰⁷Department of Community Medicine, Information and Health Decision Sciences, University of Porto, Porto, Portugal; ³⁰⁸Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium;

³⁰⁹Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium.

Involvement of humans in the study

Only secondary data was used for this study.

Authors' contributions

JVS, APM, BB, DAG, DP, EAM, FG, FF, GS, CHN, IN, JLP, JAH, KK, LM, NG, RS, RH, RH, RO, SC, SM, ZK, AF and BD have conceived and designed the study and drafted the work. JVS, FG and RH performed the data analysis. Contributions for additional authors may be found in the [appendix](#). All authors have given inputs on the interpretation of data, a substantially revised the manuscript and have approved the submitted version.

Funding

T W Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. L Belo acknowledges the support from FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. D A Bennett is supported by the UK Medical Research Council Population Health Research Unit at the University of Oxford. M Carvalho acknowledges the support from FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. A L Catapano is supported in part by the Ministero della Salute ricerca corrente. J S Chandan acknowledges the National Institute of Health Research. J Conde would like to acknowledge the European Research Council Starting Grant (ERC-StG-2019-848325). D Dias da Silva acknowledges the projects UIDP/04378/2022 and UIDB/04378/2022 of the Research Unit on Applied Molecular Biosciences UCIBIO; the project LA/P/0140/2022 of the Associate Laboratory Institute for Health and Bioeconomy i4HB; and IINFACETS-Institute of Research and Advanced Training in Health Sciences and Technologies (project PsiloPharm) and TOXRUN Toxicology Research Unit, University Institute of Health Sciences, IU-CS-CEPU, Portugal. A Douiri acknowledges support by King's Health Partners/Guy's and St Thomas Charity "MLTC Challenge Fund" (grant number EIC180702) and the NIHR Applied Research Collaboration (ARC) South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. J C Fernandes acknowledges support from Fundação para a Ciência e Tecnologia (FCT) with funding for UID/Multi/50016/2019. G Gazzard acknowledges support from NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK and Institute of Ophthalmology, University College London, UK. P S Gill acknowledges being NIHR senior investigator for the NIHR Department of Health and Social Care. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. J C Glasbey is supported by a UK National Institute of Health Research Doctoral Research Fellowship (NIHR300175). S Hussain was supported from Operational Programme Research, Development and Education "Project, Postdoc2MUNI" (No.CZ.02.2.6 9/0.0/0.0/18_053/0016952). M AB Khan acknowledges support as recipient of research grants G00003634- CMHS "NP-22-20 80, 000 AED (2021), G00003569 NP-21-13 80,000 AED, and 1976—SDG Research Program Grant 40,000 AED. B Lacey acknowledges support from UK Biobank, which is funded largely by the UK Medical Research Council and Wellcome. J A Loureiro was supported by National Funds through Fundação para a Ciência e Tecnologia (FCT) under the Scientific Employment Stimulus' Institutional Call—[CEECINST/00049/2018]. S Lorkowski acknowledges institutional support from the Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) Halle-Jena-Leipzig (Germany; German Federal Ministry of Education and Research; grant agreement number 01EA1808A). A G Mathioudakis acknowledges support by the National Institute for Health and Care Research Manchester Biomedical Research Centre (NIHR Manchester BRC) and by an NIHR Clinical Lectureship in Respiratory Medicine. J J McGrath was supported by the Danish National Research Foundation (Niels Bohr Professorship) and is employed by The Queensland Centre for Mental Health Research, which receives core funding from the Queensland Health. S Mohammed reports fellowship grant from Alexander von Humboldt Foundation, outside the submitted work. L Monasta received support from the Italian Ministry of Health, through the contribution given to the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy (RC 34/2017). P Pedersini was supported and funded by the Italian Ministry of Health—Ricerca Corrente 2021. M Pinheiro thanks FCT for funding

through program DL 57/2016 Norma transita. A Raggi acknowledges support by the Italian Ministry of Health (RRC). A Riad was supported by the project of the Ministry of Education, Youth and Sports of the Czech Republic (Systemic Risk Institute "SYRI": LX22NPO5101) and the projects of Masaryk University (MUNI/A/1402/2021 and MUNI/IGA/1104/2021). S T Skou is currently funded by a grant from Region Zealand (Exercise First) and two grants from the European Union's Horizon 2020 Research and Innovation Program, one from the European Research Council (MOBILIZE, grant agreement No 801790) and the other under grant agreement No 945377 (ESCAPE). J B Soriano is supported by Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. L Stockfelt was funded by the Swedish state under the agreement between the Swedish government and the country councils, the ALF-agreement. Johan Sundström acknowledges stock ownership in Anagram kommunikation AB and Symptoms Europe AB. R Tabares-Seisdedos is supported by the Spanish Ministry of Science and Innovation, Institute of Health Carlos III, CIBERSAM, INCLIVA (PID2021-129099OB-I00). M R Tovani-Palone acknowledges Saveetha Institute of Medical and Technical Sciences (SIMATS) for its support. J H Villafañe was supported and funded by the Italian Ministry of Health—Ricerca Corrente 2021. A Zumla acknowledges grant support from the Pan-African Network for Rapid Research, Response, Relief and Preparedness for Infectious Diseases Epidemics (PANDORA-ID-NET) ONE-HEALTH (Europe-Africa) consortium funded by the European and Developing Countries Clinical Trials Partnership, which is supported by Horizon 2020, the EU's Framework Programme for Research and Innovation.

Availability of data and materials

The datasets analysed during the current study are publicly available in the GBD 2019 Results Tool and GBD 2019 Compare repositories (<https://vizhub.healthdata.org/gbd-results/> and <https://vizhub.healthdata.org/gbd-compare>, respectively).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

J Alonso reports grants or contracts from Instituto de Salud Carlos III, Spain MINDCOVID. COV20/0711, Instituto de Salud Carlos III, Spain PROMES-U. PI20/00006, and Departament de Salut, Generalitat de Catalunya, Spain. WEMWBS-CAT, SA-2021-741, as payments to their institution, outside the submitted work. R Anuceanu reports consulting fees from Abbvie; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, B Braun, Sandoz, and Laropharm; support for attending meetings and/or travel from Abbvie; all outside the submitted work. J Ärnlov payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca and Novartis; participation on Advisory Boards for AstraZeneca, Boehringer Ingelheim, and Astella; all outside the submitted work. T W Bärnighausen reports research grants from the European Union (Horizon 2020 and EIT Health), German Research Foundation (DFG), US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius-Foundation, Wellcome Trust, Bill & Melinda Gates Foundation, KfW, UNAIDS, and the WHO; consulting fees for KfW on the OSCAR initiative in Vietnam; participation on a Data Safety Monitoring Board or Advisory Board with NIH-funded study "Healthy Options" (PIs: Smith Fawzi, Kaaya), Chair, Data Safety and Monitoring Board (DSMB), German National Committee on the "Future of Public Health Research and Education"; Chair of the scientific advisory board to the EDCTP Evaluation, Member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS (PPAH), US National Academies of Sciences, Engineering, and Medicine's Committee for the "Evaluation of Human Resources for Health in the Republic of Rwanda under the President's Emergency Plan for AIDS Relief (PEPFAR)", University of Pennsylvania (UPenn) Population Aging Research Center (PARC) External Advisory Board Member; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as Co-chair of the

Global Health Hub Germany (which was initiated by the German Ministry of Health). S Basu reports grants from the US National Institutes of Health and US Centers for Disease Control and Prevention; consulting fees from University of California San Francisco; patents planned, issued or pending, for a multi-modal patient outreach system; participation on an advisory board with La Scuola International School; leadership or fiduciary role on a board with Waymark, paid or unpaid; personal stock options in Collective Health and Waymark; all outside the submitted work. B Baune reports personal payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Janssen Cilag and LivaNova, outside the submitted work. L Belo reports other financial or non-financial interests from the FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. B Bikbov reports grants or contracts from the European Commission as personal payments, and from the Lombardy Region as payments to their institution; support for attending a meeting from the European Commission; leadership or fiduciary role, unpaid, in the Advocacy Working Group at the International Society of Nephrology; all outside the submitted work. D Buonsenso reports grants from Pfizer and Roche on long covid; support for attending meetings and/or travel from Pfizer for the ESPID meeting on covid vaccines; participation on a Data Safety Monitoring Board or Advisory Board from Pfizer for pneumococcal vaccines; all outside the submitted work. R Busse reports grants or contracts from the Innovation Fund (by Federal Joint Committee) as payments to their institution; consulting fees from Dresden hospitals and Paracelsus hospitals as personal payments; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Lilly, Abbvie and the Barmer Sickness Fund as personal payments; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid with the Government Commission on Hospital Reform; all outside the submitted work. M Carvalho reports other financial or non-financial interests from the FCT in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of UCIBIO and the project LA/P/0140/2020 of i4HB. J S Chandan reports grants or contracts from the National Institute for Health Research through College of Policing, the Youth Endowment Fund at the University of Birmingham and the Home Office. H Christensen reports grants or contracts from Veluxfonden, Novofonden, Helsefonden, Lundbeck fonden, and Tvaersfonden; royalties and licenses from Gyldendals forlag (Medicinsk Kompendium); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bayer and BMS; leadership or fiduciary role in the Action Plan for Stroke in Europe as Chair, (unpaid); all outside the submitted work. J Conde reports grants from the European Research Council Starting ERC-StG-2019-848325 (funding 1.5 M€) outside the submitted work. D Dias da Silva reports grants or contracts from faculty of Pharmacy of University of Porto as personal payment for lecturers and research activities, escola Superior de Saúde—Instituto Politécnico de Leiria as personal payment for lecturers, and Instituto Universitário de Ciências da Saúde (IUCS) as personal payment for lecturers; consulting fees from Albert Labs as personal payments and payments to their institution, Eurox Pharma as payments to their institution; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Faculty of Pharmacy of University of Porto, Escola Superior de Saúde—Instituto Politécnico de Leiria, and Instituto Universitário de Ciências da Saúde (IUCS) all as personal payments for lectures; support to attend ICT 2022 – XVth International Congress of Toxicology from Eurox Pharma; leadership or fiduciary role in the Portuguese Association of Forensic Sciences (APCF) as a member of the board; receipt of support to buy materials to research from Albert Labs and Eurox Pharma; all outside the submitted work. G Gazzard reports consulting fees from Alcon, Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Ripple, Santen, Sight Sciences, Thea, Vialase, and Zeiss; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Alcon, Allergan, Belkin, Glaukos, Ivantis, Lumibird, McKinsey, Reichert, Sight Sciences, and Thea; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with the President UK & Ireland Glaucoma Society, and as an Advisor for Glaucoma UK Charity; all outside the submitted work. N Ghith reports support for the present manuscript from Novo Nordisk Foundation (NNF16OC0021856) as a grant to the research group. P S Gill reports leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as NIHR senior investigator for the NIHR Department of Health and Social Care, UK, outside the submitted work. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social

Care. R Hrzic reports support for the present manuscript from the Department of International Health, Care and Public Health Research Institute – CAPHRI, Maastricht University, Maastricht, the Netherlands. J Jozwiak reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis and Adamed as personal fees, outside the submitted work. M AB Khan reports grants from G00003634- CMHS – NP-22–20 (80,000 AED), G00003569 NP-21–13 (80,000 AED), and 1976—SDG Research Program Grant (40,000 AED), outside the submitted work. M Klugar reports grants from Czech-Norwegian Collaboration on Meta-Research and Critical Thinking Education in Healthcare (EHP-CZ-ICP-2–009), Evidence Implementation in Clinical Practice (2020–1-DE01-KA203-005669), Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic (LTC20031), Strategic Partnership in Innovation and Development of Evidence-Based Healthcare (2019–1-CZ01-KA202-061350), all as payments to their institution; membership of Cochrane advisory board for Evidence Advocacy, unpaid; other non-financial interests as Director of Cochrane, JBI and GRADE centres of the Czech Republic; all outside the submitted work. H J Larson reports research grants to the London School of Hygiene and Tropical Medicine from the Janssen, Merck, and the MarcArthur Foundation; support for travel from Merrimon Honorary Lecture, UNC; all outside the submitted work. J V Lazarus reports grants AbbVie, Gilead Sciences, MSD, Roche Diagnostics as grants to ISGlobal; consulting fees from NovoVax; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk; unpaid participation on a Data Safety Monitoring Board or Advisory Board for a same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (The QuickStart Study): a cluster randomised control trial – Australia; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, as a Member of EASL Public Health and Policy Committee, co-chair of HIV Outcomes, and SHARE Global Health Foundation; all outside the submitted work. G Logroscino reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche Spa for a teaching course, outside the submitted work. S Lorkowski reports grants or contracts from Akcea Therapeutics Germany as payments made to their institution; consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI) as personal payments; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Akcea Therapeutics Germany, AMARIN Germany, Amedes Holding, AMGEN, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, and SYNLAB Holding Deutschland & SYNLAB Akademie, all as personal payments; support for attending meetings and/or travel from AMGEN and NOVO Nordisk Pharma as personal payments; participation on a Data Safety Monitoring Board or Advisory Board with Akcea Therapeutics Germany, AMGEN, Daiichi Sankyo Deutschland, Novartis, and Sanofi-Aventis as personal payments; all outside the submitted work. A M Madureira-Carvalho reports grants or contracts from Instituto Universitário de Ciências da Saúde (IUCS) as personal payments; consulting fees from Albert lab as personal and institutional payments and from Eurox Pharma as institutional payments; payment for lectures from Instituto Universitário de Ciências da Saúde (IUCS); support from Eurox Pharma to attend ICT 2022 – XVIth International Congress of Toxicology; leadership or fiduciary role, paid or unpaid, as Board Treasurer for the Portuguese Association of Forensic Sciences (APCF); receipt of support to buy materials for research from Albert Labs and Eurox Pharma; all outside the submitted work. A-F Mentis reports grants or contracts from 'MilkSafe: A novel pipeline to enrich formula milk using omics technologies'; a research co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH—CREATE—INNOVATE (project code: T2EDK-02222), as well as from ELIDEK (Hellenic Foundation for Research and Innovation, MIMS-860) (both outside of the present manuscript); stock or stock options in a family winery; other financial or non-financial interest as a scientific officer with BGI Group; all outside the submitted work. S Mohammed reports support for the present manuscript from the Bill and Melinda Gates Foundation; a fellowship grant from the Alexander von Humboldt Foundation, outside the submitted work. A Otoi reports grants or contracts from the Bucharest University for Economic Studies as personal payments, and from European Commission: Horizon 2020 as payments made to their institution; both outside the submitted work. R

Palladino reports grants or contracts from the UK MS Society; consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD; all outside the submitted work. C B Peterson reports grants or contracts from a consultancy with WHO Regional Office for Europe, focus on disability inclusion in health sectors as personal payments; consulting fees from the WHO Regional Office for Europe, outside the submitted work. M Pinheiro reports grants or contracts from Fundação para a Ciência e Tecnologia (FCT) (research grant) outside the submitted work. M J Postma reports stock or stock options Health-Ecore (Zeist, NL) and PAG BV (Groningen, NL), outside the submitted work. G Remuzzi reports consulting fees from Janssen, Otsuka Pharmaceuticals, Boehringer Ingelheim, Menarini Ricerche, BioCryst Pharmaceuticals, Alexion Pharmaceuticals; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma as external expert: co-chair and speaker 59th ERA congress, and from AstraZeneca Pharmaceuticals; participation on a Data Safety Monitoring Board or Advisory Board from Silence Therapeutics, Omerois Corporation, and Alexion Pharmaceuticals; all outside the submitted work. A Riad reports grants and contracts from the Ministry of Education, Youth and Sports of the Czech Republic (MŠMT) "Systemic Risk Institute (SYRI) Project Number: LX22NPO5101", from Masaryk University "MUNI/A/1402/2021", and from Masaryk University "MUNI/IGA/1104/2021", all outside the submitted work. S Sacco reports grants or contracts from Novartis, and Uriach; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Allergan-AbbVie, Abbott, Teva, Novartis, Lilly, Novonordisk, Pfizer, and Lundbeck; support for attending meetings and/or travel from Lilly, and Lundbeck; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as President elect European Stroke Organisation, and Second vice president European headache Federation; receipt of equipment, materials, drugs, medical writing, gifts or other services from NovoNordisk; all outside the submitted work. N Scarneas reports grants or contracts from EPAD as funding to their institution, and from NovoNordisk as funding to their institution; Participation as Chair of Data Safety Monitoring Board with the Albert Einstein College of Medicine funded by the NIH; outside the submitted work. V Shivarov reports one pending Bulgarian patent; stock or stock options in RSU from ICON plc; and other financial interest from PRAHS/ICON plc as salary; all outside the submitted work. S T Skou reports grants or contracts from the European Research Council as payment to their university, from the European Union's Horizon 2020 research innovation program (grant agreement No 801790), from the Region Zealand as payment to the hospital, program grant from Region Zealand (Exercise First); royalties from Munksgaard and TrustMe-Ed; payment or honoraria for one online presentations, from Nestlé Health Science; participation on as an Advisory Board Member as UK-based NIHR-funded trial PERFORM: Personalised Exercise-Rehabilitation FOR people with Multiple long-term conditions (multimorbidity, NIHR 202020); leadership or fiduciary role in other board, society, committee or advocacy group, paid, with JOSPT as associate editor; other non-financial interests as co-founder of GLA:D[®], a not-for profit initiative hosted at University of Southern Denmark aimed at implementing clinical guidelines for osteoarthritis in clinical practice; all outside the submitted work. J Sundstrom reports stock or stock options in Anagram kommunikation AB and Symptoms Europe AB, all outside the submitted work. J-D Zeitoun reports consulting fees from AbbVie, Takeda, Johnson & Johnson, and Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Elsa and ALPTIS; stock in in approximately 30 medical startups and LP in 3 investment funds; all outside the submitted work. Other remaining authors do not have any competing interest.

Author details

¹MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal. ²CINTESIS@RISE, Faculty of Medicine of the University of Porto, 4200-450 Porto, Portugal. ³Public Health Unit, ULS Santo António, Porto, Portugal. ⁴National School of Public Health. Instituto de Salud Carlos III, Madrid, Spain. ⁵Scientific-Tools.Org, Bergamo, Italy. ⁶Department of Public Health, Babeş-Bolyai University, Cluj-Napoca-Napoca, Romania. ⁷RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca-Napoca, Romania. ⁸Department for Exposure Assessment and Environmental Health Indicators, Germany Environment Agency, Berlin, Germany. ⁹Clinic of Social and Family Medicine, School of Medicine, University of Crete, Crete, Greece. ¹⁰Department

of Healthcare, Faculty of Public Health, University of Vlora, Vlora, Albania.

¹¹Independent Researcher, Rome, Italy. ¹²Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany. ¹³Centre for Disease Burden, Norwegian Institute of Public Health, Oslo, Norway. ¹⁴Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. ¹⁵National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain. ¹⁶Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ¹⁷Department of Health Economics and Social Security, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. ¹⁸Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy. ¹⁹Research group for Childhood Cancer, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark. ²⁰Medicine School, University of Applied and Environmental Sciences, Bogota, Colombia. ²¹Department of International Health, Maastricht University, Care and Public Health Research Institute – CAPHRI, Maastricht, The Netherlands. ²²Department of Non-Communicable Diseases and Injuries, Santé Publique France, Saint-Maurice, France. ²³Department of Medicine, University College Cork, College Road, Cork City, Ireland. ²⁴Department of Geriatric Medicine, Mercy University Hospital, Grenville Place, Cork City, Ireland. ²⁵Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta. ²⁶Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. ²⁷School of Public Health, University College Cork, Cork, Ireland. ²⁸Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium. ²⁹Department of Translational Physiology, Infectiology and Public Health, Ghent, Belgium.

Received: 31 May 2023 Accepted: 5 April 2024

Published online: 22 May 2024

References

- Nicole Scholz, Members' Research Service. Addressing health inequalities in the European Union, Concepts, action, state of play. Eur Parliamentary Res Serv. 2020. <https://doi.org/10.2861/567478>.
- Jutz R. Health inequalities in Europe: Does minimum income protection make a difference? *Curr Sociol*. 2021;69:99–118.
- Costantini AS, Seniori Costantini A, Gallo F, et al. Population health and status of epidemiology in Western European, Balkan and Baltic countries. *Int J Epidemiol*. 2015;44:300–23.
- Health at a glance: Europe 2020: State of health in the EU cycle. URL https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2020_82129230-en. Accessed 30 Apr 2021.
- European Commission. The health status of the European Union narrowing the health gap. Luxembourg: Office for Official Publications of the European Communities; 2003. https://openlibrary.org/books/OL16254528M/The_health_status_of_the_European_Union.
- Nuyts PAW, Hewer RMF, Kuipers MAG, et al. Youth Access to Cigarettes Across Seven European Countries: A Mixed-Methods Study. *Nicotine Tob Res*. 2020;22:1989–96.
- Garin N, Koyanagi A, Chatterji S, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. *J Gerontol A Biol Sci Med Sci*. 2016;71:205–14.
- O'Caomh R, Galluzzo L, Rodríguez-Laso Á, et al. Prevalence of frailty at population level in European ADVANTAGE Joint Action Member States: a systematic review and meta-analysis. *Ann Ist Super Sanita*. 2018;54:226–38.
- Colombo F, García-Gofiñ M, Schwierz C. Addressing multimorbidity to improve healthcare and economic sustainability. *J Comorb*. 2016;6:21–7.
- Quality of life indicators - health. URL https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Quality_of_life_indicators_-_health&oldid=566497 Accessed 5 July 2022.
- Santos JV, Lobo M, Neiva RM, et al. European Union state of health from 1990 to 2017: time trends and its enlargements' effects. *Int J Public Health*. 2020;65:175–86.
- Boncz I, Vajda R, Ágoston I, Endrei D, Sebestyén A. Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. *Eur J Health Econ*. 2014;15(Suppl 1):S137–41.
- Santos JV, Souza J, Valente J, et al. The state of health in the European Union (EU-28) in 2017: an analysis of the burden of diseases and injuries. *Eur J Public Health*. 2020;30:573–8.
- GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1160–203.
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–22.
- GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1223–49.
- GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1135–59.
- Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. *Popul Health Metr*. 2012;10:1.
- Martinez R, Soliz P, Caixeta R, Ordunez P. Reflection on modern methods: years of life lost due to premature mortality—a versatile and comprehensive measure for monitoring non-communicable disease mortality. *Int J Epidemiol*. 2019;48:1367–76.
- Global Health Data Exchange (GHDx). 2014. URL <http://www.healthdata.org/about/ghdx>. Accessed 30 Apr 2021.
- GBD Compare. 2014. URL <http://www.healthdata.org/data-visualization/gbd-compare>. Accessed 30 Apr 2021.
- R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. <https://www.R-project.org/>.
- Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. *Lancet*. 2016;388:e19–23.
- Vandenbergh D, Albrecht J. The financial burden of non-communicable diseases in the European Union: a systematic review. *Eur J Public Health*. 2020;30:833–9.
- Wang Y, Wang J. Modelling and prediction of global non-communicable diseases. *BMC Public Health*. 2020;20:822.
- Iburg KM, Charalampous P, Allebeck P, et al. Burden of disease among older adults in Europe—trends in mortality and disability, 1990–2019. *Eur J Public Health*. 2023;33(1):121–6.
- Yang X, Chen H, Sang S, Chen H, Li L, Yang X, Burden of All Cancers Along With Attributable Risk Factors in China From, to 2019: Comparison With Japan, European Union, and USA. *Front Public Health*. 1990;2022:10. <https://doi.org/10.3389/fpubh.2022.862165>.
- Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, Gavin A, Flego M, Neamtui L, Dimitrova N, Negrão Carvalho R, Ferlay J, Bettio M. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. *Eur J Cancer*. 2021;157:308–47.
- Bozhar H, McKee M, Spadea T, Veerus P, Heinävaara S, Anttila A, Senore C, Zielonke N, van Ravesteyn NT, Lansdorp-Vogelaar I, de Koning HJ, Heijnsdijk EAM. EU-TOPIA consortium. Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study. *Prev Med Rep*. 2022;26:101733.
- Sørensen HT, Bredahl Kristensen FP. Cardiovascular diseases and health inequalities in Europe—a pressing public health challenge. *Lancet Reg Health Eur*. 2023;4(33):100722.
- Castelpietra G, Knudsen AKS, Agardh EE, et al. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019. *Lancet Reg Health Eur*. 2022;1(16):100341.
- Stumbrys D, Jasilionis D, Pūras D. The burden of mental health-related mortality in the Baltic States in 2007–2018. *BMC Public Health*. 2022;22(1):1776.
- van de Laar MJ, Likatavicius G. HIV and AIDS in the European Union, 2008. *Euro Surveill*. 2009;14(47):19422.
- GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. *Lancet HIV*. 2019;6:e831–59.

35. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry*. 2021;8:416–27.
36. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet*. 2021;398:1700–12.
37. Launch of new WHO Mental Health Report: Transforming mental health for all. <https://www.who.int/news-room/events/detail/2022/06/17/default-calendar/launch-of-new-who-mental-health-report--transforming-mental-health-for-all>. Accessed 2 Jun 2022.
38. Wyper GMA, Grant I, Fletcher E, Chalmers N, McCartney G, Stockton DL. Prioritising the development of severity distributions in burden of disease studies for countries in the European region. *Arch Public Health*. 2020;78:3.
39. Fahy N, Hervey T, Greer S, et al. How will Brexit affect health services in the UK? An updated evaluation. *Lancet*. 2019;393:949–58.
40. Wyper GMA, Grant I, Fletcher E, McCartney G, Fischbacher C, Stockton DL. How do world and European standard populations impact burden of disease studies? A case study of disability-adjusted life years (DALYs) in Scotland. *Arch Public Health*. 2020;78:1.
41. Park J-H, Eum J-H, Bold B, Cheong H-K. Burden of disease due to dementia in the elderly population of Korea: present and future. *BMC Public Health*. 2013;13:293.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

BioMed Central publishes under the Creative Commons Attribution License (CCAL). Under the CCAL, authors retain copyright to the article but users are allowed to download, reprint, distribute and /or copy articles in BioMed Central journals, as long as the original work is properly cited.